I. Introduction {#s1}
===============

Glioblastoma multiforme (GBM) is the most malignant primary central nervous system tumor, and the prognosis for patients is often bleak. Currently, there are no curative treatment options for GBM, and despite rigorous therapeutic research, the survival rate of patients diagnosed with GBM remains low. Median overall survival is 15--23 months and 5-year survival is less than 6%, which is the lowest long-term survival rate of malignant brain tumors ([@B156]). An estimated 79,270 new cases of primary brain and other central nervous system (CNS) tumors were expected to be diagnosed in 2017 ([@B156]). To improve therapeutic options, studies to identify and validate single protein targets are underway. However, in most cases, targeted compounds that perform well in preclinical studies have failed expensive Phase III clinical trials in humans. Ultimately, several major factors are responsible for drug failure, including poor pharmacokinetic properties, emergence of resistance pathways, complex intratumoral heterogeneity, and suboptimal clinical trial design. Thus, there is a desperate need for an efficient approach to identify and vet potential drugs at the preclinical stage to prevent late stage failure. Genomic- and proteomic-scale analysis can identify proteins and pathways involved in the development of chemotherapeutic resistance mechanisms responsible for recurrent disease.

With the advent of TCGA (The Cancer Genome Atlas) consortium and resources, genomic analysis of cancers is at the forefront of drug discovery. Additionally, proteomics is gaining widespread use in drug discovery efforts. Quantitative proteomics can measure the expression and, in some cases, posttranslational modification status of up to and over 8000 proteins in the cell at any given time. The advent of novel proteomic techniques in the last decade, in tandem with the resources allocated to address the lack of a cure for GBM, will accelerate the discovery of a treatment and shed light on the feasibility of precision medicine.

The target and mechanism of action of many Food and Drug Administration (FDA)-approved drugs are not fully established. Of the approximately 1600 FDA-approved drugs with known targets, most belong to four classes: GPCRs (33%), ion channels (18%), nuclear receptors (16%), and kinases (3%) ([Supplemental Fig. 1](http://pharmrev.aspetjournals.org/lookup/suppl/doi:10.1124/pr.117.014944/-/DC1)) ([@B186]). This suggests uncharted proteomic space exists in which novel drug targets may be identified. Of the six drugs approved for the treatment of GBM, three act as DNA alkylators, two are kinase inhibitors, and one is a tubulin inhibitor. Burgeoning research efforts in novel treatment areas, including alternating electric field therapy (tumor-treating fields), immunotherapy, and antibody-drug conjugates are improving patient outcomes. Much of the challenge in developing a GBM therapy lies in reaching therapeutic concentrations at the target site. Few drug molecules cross the blood-brain barrier (BBB), and those that do may be exported via efflux pumps. Therefore, valid target selection, permeability, and drug pharmacokinetics are important considerations in GBM drug design.

In this review, we highlight the importance of genomic and proteomic research on identifying novel biomarkers and drug targets for GBM treatment. Additionally, we demonstrate a genomic approach to drug discovery and uncover novel potential drug targets by performing bioinformatics analysis of TCGA data. Although further validation is necessary and increased expression of some of these targets may be a response to oncogenic stress, this approach provides a list of proteins that, if inhibited alone or in combination with other targets, could effectively treat GBM. Furthermore, we address the challenges faced in the drug discovery and delivery process and discuss potential solutions to those problems. In particular, we focus on the challenge of BBB permeability, nanocarrier design, and the application of computational methods to aid compound optimization. In recent years, major clinical trials for small molecule treatment of GBM have failed because the compounds did not reach effective concentrations in the brain (i.e., gefitinib and erlotinib) ([@B3]; [@B40]). Thus, an understanding of BBB function and physiology is crucial for the development of efficacious small molecule treatment strategies and the avoidance of failed expensive clinical trials. The lack of effective treatment options for GBM emphasizes the unmet need for successful target inhibition and drug delivery strategies.

II. Current Treatment Options for Glioblastoma {#s2}
==============================================

Upon diagnosis, GBM treatment includes maximal surgical resection, followed by temozolomide and radiation ([@B205]). Due to the invasive nature of GBM, surgical resection rarely eliminates all tumor cells, and postsurgical treatment is usually necessary to prevent recurrence. Treatment varies based on the age of the patient and stage of the disease. Depending on the overall health of the patient and disease status, they may also be enrolled in relevant ongoing clinical trials.

The standard-of-care temozolomide is a DNA-alkylating agent discovered in the 1970s and approved in 2005 by the FDA to treat newly diagnosed brain tumors. The first clinical trial with temozolomide was conducted in 1993, and, of the 10 patients who received adjuvant temozolomide, five patients showed significant clinical and radiographic improvement ([@B153]). The success of this initial study prompted further successful studies of temozolomide treatment in GBM patients. In these studies, subsets of patients were more responsive to temozolomide treatment than others. Responsive patients had methyl-guanine-methyltransferase (*MGMT*) genes with methylated promoters and showed higher survival rates than patients with hypomethylated *MGMT* genes ([@B84]). MGMT is a DNA repair enzyme that repairs the N7 and O6 positions of guanine alkylated by temozolomide. Although MGMT depletion does not seem to be an effective treatment strategy ([@B170]; [@B182]), *MGMT* gene methylation status nevertheless remains an important biomarker for GBM prognosis. Although temozolomide is part of the standard chemotherapeutic regimen for GBM, it presents unwanted toxicity and does not eliminate the disease. As an alternative approach, targeted therapies may limit unwanted toxicity and more effectively block tumor proliferation.

A promising targeted treatment is the anti--vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab. Bevacizumab was first approved by the FDA in 2004 to treat metastatic colorectal cancer. Since then, it has been approved for several different types of cancer, including GBM in 2009. Angiogenesis is a key survival feature of many cancers as tumors rely on nutrients from the vasculature to proliferate. VEGF is a broad mediator of tumor neovascularization, and VEGF expression is linked with GBM tumorgenicity ([@B29]). Bevacizumab was first tested in 21 patients with malignant glioma in 2004. Patients were treated with bevacizumab at 5 mg/kg and irinotecan at 125 mg/m^2^ every 2 weeks, producing a significant 43% response rate ([@B204]). However, the Phase III "Avaglio" trial, conducted on 921 patients with newly diagnosed GBM, resulted in no overall survival benefit in bevacizumab-treated versus placebo-treated patients (median overall survival of 16.8 months for bevacizumab-treated patients and 16.7 months for placebo-treated patients) ([@B32]). A second Phase III trial, the RTOG 0825 trial, produced similar results. Out of 637 patients receiving either 10 mg/kg bevacizumab every 2 weeks or placebo, there was no significant difference in overall survival between the two groups (median overall survival of 15.7 months for bevacizumab-treated patients vs. 16.1 months for the placebo group) ([@B66]). Therefore, bevacizumab treatment is an option reserved for patients with recurrent GBM.

Almost all GBM tumors that respond to first-line therapy recur. There is no standard approach for a successful treatment of recurrent GBM. Second-line treatment may take several directions, depending on factors such as tumor size and location, previous treatments, age, and time from initial diagnosis. Treatment can include surgical resection, reirradiation, nitrosoureas, temozolomide rechallenge, bevacizumab, or tyrosine kinase inhibitors ([@B220]). Even with these treatments, median overall survival after recurrence is 6.2 months ([@B69]). In a Phase II study that led to conditional FDA approval, the longest median progression-free survival (5.6 months) was seen with a combination of bevacizumab and irinotecan ([@B58]), while longest overall survival (12 months) resulted from lomustine + bevacizumab ([@B211]). Current clinical trials involving small molecules for GBM treatment are summarized in [Table 1](#T1){ref-type="table"}; clinical trials involving biologics and other treatment strategies are reported in [Supplemental Table 1](http://pharmrev.aspetjournals.org/lookup/suppl/doi:10.1124/pr.117.014944/-/DC1).

###### 

List of clinical trials for glioblastoma treatment registered on [www.clinicaltrials.gov](http://www.clinicaltrials.gov)

Small molecules.

  No.   Drug                                  Purpose                                                                                                                                                                                        P     DR     NPE    AG      NCT number    Status
  ----- ------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----- ------ ------ ------- ------------- --------------------------------
  1     Abemaciclib                           To evaluate the efficacy of abemaciclib in recurrent GBM                                                                                                                                       2     O      47     A,S     NCT02981940   Recruiting
  2     ACP-196                               To evaluate the efficacy and safety of ACP-196 in patients with recurrent GBM who have progressed after 1 or 2 prior systemic treatment regimens                                               1/2   O      72     A,S     NCT02586857   Recruiting
  3     Afatinib                              To determine the maximum safe dose of afatinib that can be administered to people with brain cancer                                                                                            1     O      24     A,S     NCT02423525   Recruiting
  4     Aldoxorubicin                         To determine the efficacy and safety of aldoxorubicin in patients with GBM                                                                                                                     2     i.v.   28     A,S     NCT02014844   Completed ([@B71])
  5     Alisertib                             To study the side effects and best dose of alisertib when combined with fractionated stereotactic radiosurgery in treating patients with high-grade gliomas                                    1     O      24     A,S     NCT02186509   Active, not recruiting
  6     AMG-232                               To study the side effects and dosage of MDM2 inhibitor AMG-232 in patients with newly diagnosed or recurrent GBM                                                                               1     O      92     A,S     NCT03107780   Not yet recruiting
  7     Ascorbate                             To evaluate high-dose ascorbate in combination with standard of care treatment of GBM                                                                                                          2     i.v.   90     A,S     NCT02344355   Recruiting
  8     Atorvastatin                          To explore the efficacy and safety of atorvastatin in combination with RT+TMZ in patients with newly diagnosed GBM                                                                             2     O      32     A,S     NCT02029573   Completed
  9     Axitinib                              To test the efficacy of axitinib alone or in combination with lomustine for patients with recurrent GBM                                                                                        2     O      52     A,S     NCT01562197   Completed ([@B43])
  10    Axitinib + Avelumab                   To determine the efficacy of axitinib + avelumab to treat patients with recurrent GBM                                                                                                          2     O      52     A,S     NCT03291314   Recruiting
  11    AZD1390                               To test the safety and tolerability of AZD1390 in combination with radiation therapy for the treatment of brain tumors                                                                         1     i.v.   132    A,S     NCT03423628   Not yet recruiting
  12    BAL101553                             To assess side effects and best dose of BAL101553 + radiation therapy in patients with newly diagnosed GBM                                                                                     1     O      30     A,S     NCT03250299   Recruiting
  13    BBI608 (napabucasin)                  To test the efficacy of BBI608 in combination with TMZ in patients with recurrent or progressive GBM                                                                                           1/2   O      60     A,S     NCT02315534   Recruiting
  14    Belinostat                            To determine the efficacy of belinostat in patients with newly diagnosed GBM and to determine the feasibility of adding magnetic resonance spectroscopic imaging to improve patient outcomes   2     i.v.   87     A,S     NCT02137759   Recruiting
  15    Bevacizumab + Nimustine               To determine the efficacy and feasibility of bevacizumab and nimustine treatment in patients with recurrent GBM                                                                                2     i.v.   40     A,S     NCT02698280   Recruiting
  16    BGB-290                               To assess the combination of BGB-290 and TMZ in patients with newly diagnosed or recurrent GBM                                                                                                 1/2   O      300    A,S     NCT03150862   Recruiting
  17    BGJ398                                To determine the efficacy of BGJ398 in patients with recurrent resectable or unresectable GBM                                                                                                  2     O      24     A,S     NCT01975701   Active, not recruiting
  18    BLZ945                                To characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of BLZ945 against GBM                                                                     2     O      151    A,S     NCT02829723   Recruiting
  19    Buparlisib                            To test the efficacy of buparlisib plus carboplatin or lomustine in patients with recurrent GBM                                                                                                1/2   O      35     A,S     NCT01934361   Completed
  20    Cabazitaxel                           To assess the efficacy of cabazitaxel on GBM                                                                                                                                                   2     IF     24     A,S     NCT01866449   Active, not recruiting
  21    Cabozantinib                          To study the feasibility and efficacy of cabozantinib for recurrent or refractory GBM                                                                                                          2     O      10     C,A     NCT02885324   Recruiting
  22    Capecitabine                          To test the efficacy of capecitabine + bevacizumab in patients with recurrent GBM                                                                                                              1     O      12     A,S     NCT02669173   Recruiting
  23    Cediranib + Olaparib                  To evaluate to efficacy of cediranib + olaparib in patients with recurrent GBM                                                                                                                 2     O      70     A,S     NCT02974621   Recruiting
  24    Chlorogenic acid                      To determine the pharmacokinetic characteristics of chlorogenic acid in advanced GBM                                                                                                           1     i.v.   30     A       NCT02728349   Recruiting
  25    Chloroquine                           To assess the safety of chloroquine addition to chemoradiation in newly diagnosed GBM                                                                                                          1     O      9      A,S     NCT02378532   Active, not recruiting
  26    Crenolanib                            To investigate crenolanib monotherapy in patients with recurrent/refractory GBM with PDGFRA gene amplification                                                                                 2     O      33     A,S     NCT02626364   Recruiting
  27    Crizotinib                            To assess the safety, efficacy, and safety of crizotinib in combination with RT+TMZ in patients with newly diagnosed GBM                                                                       1     O      24     A,S     NCT02270034   Recruiting
  28    Dacomitinib                           To assess the efficacy and safety of dacomitinib in patients with recurrent GBM with EGFR gene amplification and/or EGFRvIII mutation.                                                         2     O      64     A,S     NCT01520870   Active, not recruiting
  29    Dexanabinol                           To determine the maximum safe dose of dexanabinol that can be administered to people with brain cancer                                                                                         1     i.v.   26     A,S     NCT01654497   Completed
  30    Dimethyl fumarate                     To test the safety of dimethyl fumarate in combination with RT+TMZ in patients with newly diagnosed GBM                                                                                        1     O      12     A,S     NCT02337426   Active, not recruiting
  31    Disulfiram                            To assess the effects of proteasome inhibition in patients with GBM                                                                                                                            1     O      20     A,S     NCT01907165   Active, not recruiting
  32    DM-CHOC-PEN                           To test the efficacy of DM-CHOC-PEN in patients with GBM                                                                                                                                       2     i.v.   27     A,S     NCT02038218   Completed
  33    Dovitinib                             To determine a safe and tolerable dose of dovitinib in patients with relapsed GBM                                                                                                              1     O      12     A,S     NCT01972750   Completed ([@B190])
  34    Dovitinib                             To determine the efficacy of dovitinib on recurrent GBM                                                                                                                                        2     O      33     A,S     NCT01753713   Completed ([@B4])
  35    Epacadostat                           To determine the efficacy of epacadostat in combination with nivolumab for patients with GBM                                                                                                   2     O      291    A,S     NCT02327078   Recruiting
  36    Fingolimod                            To evaluate the efficacy of fingolimod in patients with bevacizumab-resistant GBM                                                                                                              1     O      5      A,S     NCT02490930   Completed
  37    G-202 (mipsagargin)                   To evaluate the activity, safety, and CNS exposure of G-202 in patients with recurrent or progressive GBM                                                                                      2     i.v.   26     A,S     NCT02067156   Completed, Publication Awaited
  38    GDC-0084                              To evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics and efficacy of GDC-0084 in patients with progressive or recurrent GBM                                             1     O      29     A,S     NCT01547546   Completed ([@B238])
  39    HMPL-813                              To evaluate epitinib to treat GBM patients with EGFR gene amplification                                                                                                                        1     O      29     A,S     NCT03231501   Not yet recruiting
  40    INC280 + Buparlisib                   To assess the safety of the combination of INC280 and buparlisib in patients with recurrent GBM                                                                                                1/2   O      42     A,S     NCT01870726   Completed ([@B223])
  41    Indoximod                             To assess the effect of indoximod in patients with newly diagnosed GBM                                                                                                                         1/2   O      144    C,A,S   NCT02052648   Recruiting
  42    Ixazomib                              To determine the tissue concentration of ixazomib citrate                                                                                                                                      1     O      3      A,S     NCT02630030   Recruiting
  43    JP001                                 To evaluate the effect of JP001 in combination with standard chemoradiation on increasing overall survival of patients with newly diagnosed GBM                                                2/3   O      264    A,S     NCT03008148   Not yet recruiting
  44    Lapatinib                             To test the safety and effects of a combination of lapatinib, plus RT+TMZ in patients with newly diagnosed GBM                                                                                 2     i.v.   70     A,S     NCT01591577   Recruiting
  45    LB100                                 To determine blood-brain barrier permeability of LB100                                                                                                                                         1     i.v.   20     A,S     NCT03027388   Not yet recruiting
  46    LOXO-101                              To determine the efficacy of LOXO-101 in the treatment of solid tumors                                                                                                                         2     O      151    C,A,S   NCT02576431   Recruiting
  47    LY2157299                             To test the efficacy of LY2157299 in combination with lomustine in patients with recurrent GBM                                                                                                 2     O      180    A,S     NCT01582269   Active, not recruiting
  48    LY2228820                             To determine an appropriate dose of LY2228820 in combination with TMZ and radiotherapy in patients with newly diagnosed GBM                                                                    1/2   O      50     A,S     NCT02364206   Recruiting
  49    Macitentan                            To test the safety of macitentan in patients with newly diagnosed GBM                                                                                                                          1     O      30     A,S     NCT02254954   Completed
  50    Marizomib                             To establish the impact of marizomib on overall survival of patients with GBM                                                                                                                  3     i.v.   750    A,S     NCT03345095   Not yet recruiting
  51    Marizomib                             To determine the efficacy of marizomib in patients with newly diagnosed GBM                                                                                                                    1     i.v.   48     A,S     NCT02903069   Recruiting
  52    Mebendazole                           To determine the safety and side effects for increasing doses of mebendazole for recurrent or progressive pediatric brain tumors                                                               1     O      21     C,A     NCT02644291   Recruiting
  53    Mibefradil                            To determine the safety of mibefradil and hypofractionated re-irradiation therapy in recurrent GBM                                                                                             1     O      24     A,S     NCT02202993   Completed
  54    Nabiximols                            To determine the safety of nabiximols in combination with TMZ in patients with recurrent GBM                                                                                                   1/2   O      6      A,S     NCT01812603   Completed ([@B222])
  55    NVX-108                               To test the safety, tolerability, and effectiveness of NVX-108                                                                                                                                 1     i.v.   25     A,S     NCT02189109   Active, not recruiting
  56    Olaparib                              To determine efficacy of olaparib in patients with glioma, cholangiocarcinoma, or solid tumors with IDH1 or IDH2 mutations                                                                     2     O      75     A,S     NCT03212274   Not yet recruiting
  57    ONC201                                To test efficacy of ONC201 in patients with recurrent GBM                                                                                                                                      2     O      30     A,S     NCT02525692   Recruiting
  58    Ortataxel                             To evaluate the efficacy of ortataxel in recurrent GBM                                                                                                                                         2     i.v.   64     A,S     NCT01989884   Suspended
  59    Palbociclib Isethionate               To test the side effects and best dose of palbociclib isethionate in treating younger patients with central nervous system tumors                                                              1     O      55     C,A     NCT02255461   Recruiting
  60    Pazopanib                             To assess pazopanib in combination with TMZ in patients with newly diagnosed GBM after surgery and RT-CT                                                                                       1/2   O      51     A,S     NCT02331498   Recruiting
  61    Pembrolizumab + Vorinostat + TMZ      To test the safety and tolerability of vorinostat and pembrolizumab, in combination with TMZ and radiotherapy                                                                                  1     O      32     A,S     NCT03426891   Not yet recruiting
  62    Perifosine + Torisel (Temsirolimus)   To test the effectiveness of perifosine and torisel in patients with recurrent or progressive GBM                                                                                              2     O      10     A,S     NCT02238496   Active, not recruiting
  63    Plerixafor                            To determine the safety of plerixafor after radiation therapy and TMZ in patients with newly diagnosed GBM                                                                                     1/2   O      29     A,S     NCT01977677   Active, not recruiting
  64    PLX3397                               To test the efficacy of PLX3397 in combination with radiation therapy (RT) + TMZ in patients with newly diagnosed GBM                                                                          1/2   O      65     A,S     NCT01790503   Active, not recruiting
  65    Ponatinib                             To evaluate the efficacy of ponatinib in recurrent GBM                                                                                                                                         2     O      32     A,S     NCT02478164   Active, not recruiting
  66    PQR309                                To evaluate the dual pan-PI3K and mTOR inhibitor in patients with first progression of GBM                                                                                                     2     O      \>35   A,S     NCT02850744   Active, not recruiting
  67    PT2385                                To study efficacy of HIF-2 alpha inhibitor PT2385 in patients with recurrent GBM                                                                                                               2     O      35     A,S     NCT03216499   Recruiting
  68    Regorafenib                           To evaluate the role of regorafenib in prolonging the overall survival of GBM patients                                                                                                         2     O      112    A,S     NCT02926222   Active, not recruiting
  69    Ribociclib                            To assess the ability of ribociclib to inhibit CDK4/CDK6/RB/E2F signaling and cell proliferation/viability in core and infiltrating tumor tissues obtained from patients with recurrent GBM    1     O      20     A,S     NCT02345824   Recruiting
  70    Sapanisertib                          To determine blood-brain barrier permeability and efficacy of sapanisertib                                                                                                                     1     O      40     A,S     NCT02133183   Recruiting
  71    Sapanisertib                          To determine the best dose of sapanisertib in combination with bevacizumab in patients with recurrent GBM or advanced solid tumors                                                             1     O      23     A,S     NCT02142803   Recruiting
  72    Selinexor                             To evaluate the efficacy and safety of selinexor in patients with recurrent GBM                                                                                                                2     O      125    A,S     NCT01986348   Active, not recruiting
  73    Sunitinib                             To determine the effectiveness of a combination of sunitinib, TMZ, and RT in newly diagnosed GBM patients harboring tumors with unmethylated *MGMT* promoter                                   2     O      45     A,S     NCT02928575   Recruiting
  74    Sunitinib                             To evaluate the effect of high-dose, intermittent sunitinib in patients with recurrent GBM                                                                                                     2/3   O      100    A,S     NCT03025893   Not yet recruiting
  75    Tesevatinib                           To assess the efficacy of tesevatinib monotherapy in recurrent GBM                                                                                                                             2     O      40     A,S     NCT02844439   Active, not recruiting
  76    TG02                                  To determine safety and efficacy of TG02 in patients with recurrent GBM and anaplastic astrocytoma                                                                                             1/2   O      152    A,S     NCT02942264   Recruiting
  77    TH-302                                To determine the safety and efficacy of TH-302 in combination with bevacizumab for GBM following bevacizumab failure                                                                           2     O      33     A,S     NCT02342379   Active, not recruiting
  78    Tipifarnib                            To test the safety and effectiveness of tipifarnib for newly diagnosed GBM                                                                                                                     1     O      19     A,S     NCT02227901   Completed
  79    Tivozanib                             To test the safety and effectiveness of tivozanib for recurrent GBM                                                                                                                            2     O      10     A,S     NCT01846871   Completed ([@B105])
  80    TPI 287                               To evaluate the safety, maximum tolerated dose (MTD), and efficacy of TPI 287 in combination with bevacizumab in patients with GBM                                                             2     i.v.   17     A,S     NCT02047214   Terminated
  81    Trametinib                            To investigate the activity of dabrafenib in combination with trametinib in children and adolescent patients with *BRAF* V600 mutation-positive relapsed or refractory GBM                     2     O      40     C       NCT02684058   Recruiting
  82    TRC102                                To evaluate the combination of TRC102 and TMZ in patients with recurrent GBM                                                                                                                   2     O      66     A,S     NCT02395692   Active, not recruiting
  83    Ubidecarenone                         To study the side effects and dosage of ubidecarenone injectable nanosuspension in patients with recurrent GBM or gliosarcoma                                                                  1     i.v.   10     A,S     NCT03020602   Recruiting
  84    USL311                                To assess the safety and efficacy of USL311 alone and in combination with lomustine in patients with relapsed or recurrent GBM                                                                 2     O      120    A,S     NCT02765165   Recruiting
  85    VAL-083                               To investigate the efficacy of VAL-083 in patients with TMZ-bevacizumab recurrent GBM                                                                                                          3     i.v.   180    AS      NCT03149575   Recruiting
  86    VAL-083                               To determine the efficacy of VAL-083 on unmethylated *MGMT* recurrent GBM                                                                                                                      2     i.v.   48     A,S     NCT02717962   Recruiting
  87    Veliparib                             To determine efficacy of veliparib + TMZ in patients with newly diagnosed GBM                                                                                                                  2/3   O      440    A,S     NCT02152982   Recruiting
  88    Vistusertib                           To determine the efficacy of mTORC1/2 kinase inhibitor vistusertib in previously treated GBM                                                                                                   1/2   O      52     A,S     NCT02619864   Recruiting
  89    Vorinostat                            To determine the efficacy of vorinostat + bevacizumab in patients with recurrent GBM                                                                                                           2     O      48     A,S     NCT01738646   Completed ([@B63])
  90    *β*-elemene                           To determine the efficacy of *β*-elemene to maintain the health of patients with newly diagnosed malignant gliomas following standard treatment                                                3     i.v.   100    A,S     NCT02629757   Recruiting

A, adult (18--60 years old); AG, age groups; C, child (\<18 years old); CDK4/6, cyclin-dependent kinase 4/6; DR, delivery route; IF, infusion; i.v., intravenous; MDM2, mouse double minute 2 homolog; mTOR, mammalian target of rapamycin complex 1; NPE, number of patients enrolled; O, oral; P, phase; S, senior (\>60 years old); TMZ, temozolomide.

III. Molecular Diagnostic Signature of Glioblastoma {#s3}
===================================================

Glioblastoma is a grade IV glioma and the most malignant astrocytoma ([Fig. 1](#F1){ref-type="fig"}) ([@B199]). GBM tumors consist of a complex mixture of heterogeneous cells, complicating the search for the cell of origin. Previously, GBM was thought to originate from neural stem cells. However, studies have suggested that gliomas may differentiate directly from progenitor cells, and the type of progenitor cell each tumor originates from dictates their chemosensitivity ([@B161]). Until recently, GBM tumors have been diagnosed histologically and are characterized by increased cell density, abnormal cell types (atypia), areas of necrosis, and robust angiogenesis ([Fig. 2](#F2){ref-type="fig"}). This histologic diagnosis hinders therapeutic approaches at personalized therapy. TCGA project improved characterization of GBM tumors with whole genome sequencing and identified key oncogenic signaling pathways to further classify tumor types. The molecular aberrations required for gliomagenesis include: mutations in the P53, retinoblastoma (RB), and receptor tyrosine kinase/Ras/phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) signaling pathways ([Fig. 3](#F3){ref-type="fig"}) ([@B22]). RB and P53 are tumor suppressors that lose function in several cancers ([@B236]; [@B55]). Additionally, epithelial growth factor receptor (EGFR) expression is amplified in some GBM tumors, leading to increased cell proliferation through the receptor tyrosine kinase/Ras/PI3K/AKT signaling pathway ([@B93]). Through TCGA project, tumors were also profiled with reverse phase protein array, a high-throughput technique similar to Western blotting that detects and quantifies protein expression levels. Out of 171 antibodies, 127 correlated with transcriptomal subtype, and signaling pathway alterations were confirmed, including increased EGFR, Notch1, and Notch3 expression and activated MAPK pathway signaling ([@B22]). Although this is a useful tool, only 171 antibodies were used in this study and therefore only 171 gene products could be profiled, providing a limited scope of potential novel drug targets. TCGA results were used by the World Health Organization to describe novel guidelines for GBM diagnosis to supplement histologic findings with the mutation status of several biomarkers of GBM, including *IDH1/2*, *ATRX*, and Histone Cluster 1 H3 Family Member A (HIST1H3A or H3F3A) (mutation at position K27M or simply H3-K27M mutation) ([@B178]). The novel classification of GBM subtypes will aid patient stratification and the development of targeted therapeutics based on genetics.

![Classification of brain tumors as reported from the Central Brain Tumor Registry of the United States ([@B156]). Numbers in parentheses indicates incidence or cases per 100,000 individuals and are age-adjusted to the 2000 United States standard population.](pr.117.014944f1){#F1}

![Common characteristics and diagnostic markers of World Health Organization grade IV glioma compared with lower-grade gliomas. Object images obtained from Servier Medical Art by Servier.](pr.117.014944f2){#F2}

![Canonical gliomagenesis mediators EGFR, P53, and retinoblastoma protein (RB1) are important for cancer signaling. EGFR is amplified or mutated to the constitutively active EGFRvIII and propagates kinase signaling cascades to promote proliferation, invasion, and angiogenesis. P53 is a tumor suppressor that is mutated in GBM, allowing B-cell lymphoma 2 (BCL2) to inhibit apoptosis. RB is another tumor suppressor that, when inactivated, releases E2F transcription factor 1 (E2F1) to activate cell cycling and growth. Percentages of aberrations of commonly mutated genes (in yellow) are reported, determined from TCGA analysis of patient samples ([@B22]).](pr.117.014944f3){#F3}

Molecular profiling has been used to classify GBM into four subtypes: Classic, Mesenchymal, Proneural, and Neural. Expression and aberrations of specific genes associated with each subtype have been identified ([@B227]). All Classic GBM tumors contain chromosome 7 amplification and chromosome 10 loss, and almost all (97%) display *EGFR* amplification ([@B227]). Mesenchymal GBM tumors show loss of *NF1*, contain markers of epithelial-to-mesenchymal transition (*CD44* and *MERTYK*), and highly express genes in the tumor necrosis factor super family and NF-*κ*B pathways. Alterations of *PDGFRA* and point mutations in the *IDH1* gene are characteristic of Proneural subtypes. Tumors with expression of neural markers *NEFL*, *GABRA1*, *SYT1*, and *SLC12A5* are classified as the Neural subtype. Of these subtypes, patients classified with the Proneural subtype generally had a longer overall survival, although the results were not statistically significant. Furthermore, the Proneural subtype is most common in younger patients. However, of the four subtypes, the Proneural subtype seemed the least responsive to aggressive treatment (concurrent chemo- and radiotherapy or more than three subsequent cycles of chemotherapy) ([@B227]).

Improvements in tumor profiling may drastically alter how GBM is treated and may improve the fidelity of new diagnoses. Furthermore, treatment of each tumor subtype may be individualized for optimal success. Although no targeted therapies have been approved for GBM yet, these diagnostic criteria may lead to more effective personalized treatments. Moreover, targeted therapies should be evaluated in a specific GBM subtype for optimal response. Further complicating the development of targeted treatments is the fact that a single cell of origin may not exist because of the cellular complexity of GBM. Conversely, multiple factors lead to the disease, and in fact, the cell of origin may not be the cell type that contains the transforming mutation. However, deciphering the cell of origin of GBM may be important to identify properly targets for drug discovery, stratify patient diagnosis, and optimize an effective treatment strategy.

IV. Characteristics of Protein Expression in Glioblastoma {#s4}
=========================================================

Dynamic signaling pathways govern cancer cell proliferation. A major consequence of cancer signaling is an imbalance in protein expression to allow the cells to evade apoptosis, proliferate, and metastasize. Approximately 40% of GBM tumors are characterized by amplification and overexpression of EGFR, an effector of several signaling cascades that aid tumor growth, angiogenesis, migration, and metastatic spread ([@B22]). EGFR is a receptor tyrosine kinase that, upon ligand binding, dimerizes and activates downstream signaling through the Ras/PI3K/AKT pathway. EGFR overexpression and EGFRvIII amplification may be prognostic markers that correlate with decreased overall survival of GBM patients ([@B197]); however, a recent meta-analysis disputes this claim ([@B28]). Nevertheless, because EGFR amplification and mutations promote glioma growth and survival, EGFR has been proposed as an attractive therapeutic target. Unfortunately, several clinical trials with EGFR inhibitors have failed, likely due to poor BBB permeability, intratumoral heterogeneity, and the difference between local versus systemic administration ([@B237]). Gliomagenesis is driven by mutations such as EGFRvIII, and those gene mutations promote tumor growth and proliferation through protein expression networks.

Large-scale proteomic research has shown that GBM tumors have increased expression of membrane proteins involved in cellular function and maintenance (*P* = 2.03 × 10^−8^), protein synthesis (*P* = 7.74 × 10^−11^), cell-to-cell signaling and interaction (*P* = 1.82 × 10^−10^), cellular movement (*P* = 1.34 × 10^−8^), and antigen presentation (*P* = 2.24 × 10^−7^) compared with normal brain tissue ([Fig. 4](#F4){ref-type="fig"}) ([@B167]). More specifically, GBM tumors had increased expression of membrane proteins involved in acute phase response signaling, caveolar-mediated endocytosis signaling, and calcium signaling ([@B167]). To confirm these findings, we evaluated the 25 genes shown in [Fig. 4](#F4){ref-type="fig"} using Pharos drug target survey software ([@B146]). RNASeq expression of these genes was classified as medium to high in normal brain tissue and 19 out of 25 were significantly upregulated in GBM ([Supplemental Table 2](http://pharmrev.aspetjournals.org/lookup/suppl/doi:10.1124/pr.117.014944/-/DC1)).

![Signaling pathways involving membrane proteins upregulated in GBM as determined by LC-MS/MS and iTRAQ. Results are from proteomic analysis of human GBM tumors with Ingenuity Pathway Analysis software ([@B167]). Representative genes from each category are shown.](pr.117.014944f4){#F4}

Proteomic approaches have identified proteins that are involved in chemotherapeutic resistance. For example, a study using 2D gel electrophoresis (2DGE) and mass spectrometry identified that lipocalin 2 and integrin *β*3 were downregulated in BCNU-resistant rat models of glioma ([@B206]). Furthermore, 2DGE coupled with liquid chromatography-mass spectrometry analysis identified several proteins important for the invasive properties of gliomas ([@B134]). In particular, annexin A2 was highly expressed in an angiogenesis-dependent cell line ([@B134]), and its overexpression further correlated with tumor aggressiveness and patient survival ([@B136]).

Although many other proteins have been found to contribute to GBM tumor growth, for this review, we will focus on targets that have been discovered through proteomic approaches and TCGA data mining. Some examples of proteins overexpressed in GBM that may represent novel drug targets that were not discovered via proteomic approaches include heat-shock protein 47 ([@B102]), cathepsin L ([@B248]), glycoprotein nonmetastatic melanoma protein B ([@B151]), transcription factor 12 ([@B67]), targeting protein for Xenopus kinesin-like protein 2 ([@B72]), and B-cell CLL/lymphoma 3 (BCL3) ([@B243]). Due to the characteristic intratumoral heterogeneity of GBM, it is likely that a single target approach will not be effective, and appropriate drug combinations will be necessary.

V. Emerging Targets in Glioblastoma {#s5}
===================================

Numerous proteins are overexpressed in GBM, and abundant research has identified potential targets; however, extensive genomic and proteomic research suggests that tumor heterogeneity will likely render GBM unresponsive to single agent therapy. Of equal importance to target discovery is biomarker identification. Disease biomarkers can be used for early diagnosis and monitoring responsiveness to treatment.

A. Biomarker Identification {#s6}
---------------------------

Biomarkers have been used successfully as tools for cancer diagnosis. Prostate cancer was one of the first to benefit significantly with the discovery of prostate specific antigen to inform early diagnosis and response to treatment. In addition, biomarkers have been discovered for ovarian, head and neck, lung, and breast cancer, among others ([@B163]; [@B225]; [@B245]; [@B201]). Gliomas are characterized in the clinic by *IDH1* and *IDH2* mutations and *MGMT* gene promoter methylation status to better inform treatment strategies; however, for GBM, proper prognostic biomarkers do not yet exist. By studying glioma tumorigenesis in detail, prognostic markers can be identified. Better prognostic markers would allow physicians to diagnose and begin treatment of GBM at early onset, possibly preventing disease progression.

Several groups have used proteomic techniques to analyze GBM and identify potential biomarkers for early diagnosis. For example, small extracellular vesicles transporting RNA and protein between cells can help clinicians diagnose and begin treatment of GBM at an earlier stage. Small extracellular vesicles in the cerebrospinal fluid carry important microRNA that could be used as biomarkers ([@B5]). In addition, the oncometabolite 2-hydroxyglutarate (2-HG) has been studied as a noninvasive biomarker in gliomas. In one study, urinary 2-HG levels were elevated in patients diagnosed with *IDH1*-mutant gliomas ([@B49]). However, it is still unclear whether 2-HG levels could be used as a diagnostic measure for *IDH1*-mutant GBM and whether 2-HG levels could determine patient health outcome in response to chemotherapy and radiation. A computational approach was used to identify dysregulated pathways associated with short-term survival including proteins associated with gene ontology terms "protein kinase cascade" and "NF-κB pathway" ([@B160]). Despite this research, novel disease biomarkers identified with mass spectrometry-based proteomics have yet to reach the clinic ([@B41]).

B. Drug Discovery Targets {#s7}
-------------------------

Genomic and proteomic techniques inform the development of precision medicine. The evolution of large-scale proteomic efforts is likely to benefit future drug discovery, and information on genomic events in GBM could lead to valuable insights about protein target candidates. Using TCGA GBM project cohort genomic analysis, we identified 20 genes with high expression that correlates with poor overall survival. These genes encode for proteins that promote the aggressive nature of GBM tumors and therefore may be important drug targets. However, further validation is necessary to confirm that the increased expression is not a response to oncogenic stress.

### 1. Gene Expression Associated with Reduced Patient Survival {#s8}

In an effort to better understand the landscape of known and unknown GBM drug targets based on available gene expression data, we performed an analysis on 141 GBM samples from the TCGA cohort with both survival metadata and RNASeq expression data (<http://cancergenome.nih.gov/>). Patient sample RNASeq RSEM-normalized gene expression values and survival metadata were sourced from the TCGA GDAC Firehose ([@B23]). When multiple samples were available for a given patient, barcodes were sorted alphabetically and the first was selected for analysis.

GBM patient samples were evaluated for reduced survivability by comparing survival outcomes for patients with high and low expression of each gene ([Fig. 5](#F5){ref-type="fig"}). Thresholding for high and low expression patient populations was evaluated using five different quantile cutoffs: 95%, 90%, 75%, 50%, and 25%. A log-rank test statistic was calculated for each cutoff to compare the survival distributions of high and low expression patient populations with the null hypothesis that there was no difference in survival curves. *P*-values were FDR-adjusted across all diseases, quantile cutoffs, and genes evaluated. To reduce over-fitting of a single cutoff per gene, genes for which the high expression population was associated with reduced survivability were required to have FDR-adjusted *P*-values ≤0.1 for at least two quantile cutoffs. Survival test statistics were calculated in R using the survival package ([@B174]).

![Twenty genes were identified as associated with reduced survivability in the TCGA GBM patient cohort profiled with RNASeq expression data. Patients were stratified by high and low gene expression based on one of five expression percentile thresholds. Kaplan-Meier survival plots are shown with patients having increased expression in red and all other GBM patients shown in green. Nonadjusted *P* values generated using the log-rank test are shown. All *P* values shown survived multiple testing corrections (qValue ≤ 0.1) across all 5 percentile thresholds and 20,531 genes.](pr.117.014944f5){#F5}

Twenty genes were identified as significantly associated with reduced survivability using the criteria described in the previous paragraph ([Table 2](#T2){ref-type="table"}). To further validate the statistical significance of all 20 genes, a univariate Cox proportional hazards analysis was performed using thresholds for high and low expression shown in [Fig. 5](#F5){ref-type="fig"}. All 20 genes remained significantly associated with reduced survival ([Supplemental Table 3](http://pharmrev.aspetjournals.org/lookup/suppl/doi:10.1124/pr.117.014944/-/DC1)). Additionally, a multivariate Cox proportional hazards analysis was performed taking into account clinical properties found to be significantly (Cox univariate *P* value \<0.05) associated with reduced survivability including age, Karnofsky performance score, postoperative drug treatment, and radiation therapy ([Supplemental Table 4](http://pharmrev.aspetjournals.org/lookup/suppl/doi:10.1124/pr.117.014944/-/DC1)). All but one gene (*NDEL1*) remained significant (*P* value \<0.05) after controlling for significant clinical properties, but still exhibited borderline significance (*P* value = 0.065). It should be noted that chemotherapy and radiation treatments were received by 83% and 84% of patients, respectively and were associated with improved survival (*P* value = 0.00017 and 0.000001, respectively).

###### 

Gene list and descriptions from DAVID bioinformatics database (<https://david.ncifcrf.gov>)

  No.   Name             Full Name                                              Description                                                                                                                                                                                                                                                                                                                                   Reference
  ----- ---------------- ------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------
  1     *BOC*            BOC cell adhesion associated, oncogene regulated       Component of a cell-surface receptor complex that mediates cell-cell interactions between muscle precursor cells                                                                                                                                                                                                                              [@B217]
  2     *CLEC4GP1*       C-type lectin domain family 4 member G pseudogene 1    Function unknown                                                                                                                                                                                                                                                                                                                              
  3     *ELOVL6*         ELOVL fatty acid elongase 6                            Fatty acid elongase specific to C12-C16 saturated and monounsaturated fatty acids                                                                                                                                                                                                                                                             [@B50]
  4     *EREG*           epiregulin                                             May be a mediator of localized cell proliferation                                                                                                                                                                                                                                                                                             [@B180]
  5     *ESR2*           estrogen receptor 2                                    Nuclear hormone receptor that binds estrogens with an affinity similar to that of ESR1 and activates expression of reporter genes containing estrogen response elements in an estrogen-dependent manner                                                                                                                                       [@B16], [@B188]
  6     *FDCSP*          follicular dendritic cell secreted protein             Can bind to the surface of B-lymphoma cells, but not T-lymphoma cells, consistent with a function as a secreted mediator acting upon B-cells                                                                                                                                                                                                  [@B232], [@B90]
  7     *FURIN*          furin, paired basic amino acid cleaving enzyme         Release of mature proteins from their proproteins by cleavage of -Arg-Xaa-Yaa-Arg-\|-Zaa- bonds, where Xaa can be any amino acid and Yaa is Arg or Lys and regulates TGF-*β* bioavailability                                                                                                                                                  [@B165]
  8     *FUT8-AS1*       fucosyltransferase 8 antisense RNA 1                   Fucosylation of proteins, including EGFR                                                                                                                                                                                                                                                                                                      [@B120]
  9     *GZMB*           granzyme B                                             This enzyme is necessary for target cell lysis in cell-mediated immune responses. It cleaves after Asp. Seems to be linked to an activation cascade of caspases (aspartate-specific cysteine proteases) responsible for apoptosis execution. It has been associated with both tumor progression and regression, in a case-dependent manner.   [@B137], [@B183]
  10    *IRX3*           iroquois homeobox 3                                    Belongs to the TALE/IRO homeobox family and may have a direct functional relationship to both obesity and type 2 diabetes. IRX3 is a proneural gene important for neuronal differentiation.                                                                                                                                                   [@B255], [@B193]
  11    *LITAF*          lipopolysaccharide induced TNF factor                  Probable role in regulating transcription of specific genes. May regulate through NF-*κ*B1 the expression of the CCL2/MCP-1 chemokine. May play a role in TNF-alpha gene expression.                                                                                                                                                          [@B265]
  12    *NDEL1*          nudE neurodevelopment protein 1 like 1                 Facilitates the polymerization of neurofilaments from the individual subunits NEFH and NEFL. Required for organization of the cellular microtubule array and microtubule anchoring at the centrosome.                                                                                                                                         [@B88]
  13    *NKX3-1*         NK3 homeobox 1                                         Transcription factor, which binds preferentially the consensus sequence 5′-TAAGT\[AG\]-3′ and can behave as a transcriptional repressor. Could play an important role in regulating proliferation of glandular epithelium and in the formation of ducts in prostate.                                                                          [@B20]
  14    *PODNL1*         podocan like 1                                         Belongs to the small leucine-rich proteoglycan (SLRP) family                                                                                                                                                                                                                                                                                  [@B86], [@B253], [@B216]
  15    *PTPRN*          protein tyrosine phosphatase, receptor type N          Implicated in neuroendocrine secretory processes. May be involved in processes specific for neurosecretory granules, such as their biogenesis, trafficking or regulated exocytosis or may have a general role in neuroendocrine functions.                                                                                                    [@B246], [@B17]
  16    *QSOX1*          quiescin sulfhydryl oxidase 1                          Catalyzes the oxidation of sulfhydryl groups in peptide and protein thiols to disulfides with the reduction of oxygen to hydrogen peroxide. May contribute to disulfide bond formation in a variety of secreted proteins.                                                                                                                     [@B108]
  17    *SEMA4F*         semaphorin 4F                                          Estrogen-regulated semaphorin ligand with growth cone collapse activity against retinal ganglion-cell axons                                                                                                                                                                                                                                   [@B158]
  18    *TH*             tyrosine hydroxylase                                   Plays an important role in the physiology of adrenergic neurons                                                                                                                                                                                                                                                                               [@B215]
  19    *VEGFC*          vascular endothelial growth factor C                   Growth factor active in angiogenesis and endothelial cell growth, stimulating proliferation and migration. Has effects on the permeability of blood vessels. May function in angiogenesis of the venous and lymphatic vascular systems during embryogenesis, and in the maintenance of differentiated lymphatic endothelium in adults.        [@B39], [@B45]
  20    *C20orf166AS1*   chromosome 20 open reading frame 166 antisense RNA 1   Long noncoding RNA                                                                                                                                                                                                                                                                                                                            [@B91]

TNF, tumor necrosis factor.

Several of the 20 significant genes ([Table 2](#T2){ref-type="table"}) encode proteins involved in EGFR signaling. Our results reveal novel EGFR signaling proteins that may have more prominent roles than previously thought. These proteins include proteases (FURIN, GZMB, and NDEL1), transcription factors (LITAF, IRX3, NKX3-1, and VEGFC), and receptors (ER*β*, BOC, EREG, and PTPRN). Agglomerative hierarchical clustering was performed using the 20 significant genes across TCGA GBM patients, and patients were stratified based on cluster membership. One cluster group had higher average expression across the 20 genes, and this higher expression corresponded with reduced time to death and disease-free survival ([Fig. 6A](#F6){ref-type="fig"}). Patients belonging to the cluster group with higher average expression had significantly reduced survival compared with those not included. Survival stratification significance (*P* = 5.59 × 10^−11^) was greater when evaluating by cluster group across all 20 genes compared with any of the 20 genes separately ([Fig. 6B](#F6){ref-type="fig"}). Gene expression association with poor overall survival was further validated by applying survival test statistics to samples from three independent GBM cohorts ([@B56]; [@B145]; [@B256]). Eight of the 20 genes (*LITAF*, *FURIN*, *VEGFC*, *C20orf166*-*AS1*, *ELOVL6*, *PODNL1*, *ESR2*, and *QSOX1*) were significantly associated with reduced survivability in at least one additional GBM cohort ([Supplemental Fig. 2](http://pharmrev.aspetjournals.org/lookup/suppl/doi:10.1124/pr.117.014944/-/DC1)). This additional validation supports the importance of the overexpression of these genes in the context of GBM.

![(A) Hierarchical clustering was performed to identify groups of patients with similar RNASeq expression of 20 genes associated with reduced survivability in the TCGA GBM patient cohort. (B) Patients stratified using clustering dendrogram assignment into high and low expression groups showed significant differences in survival. Heatmap z-scores were calculated per gene. Agglomerative hierarchical clustering with complete linkage was performed using Euclidean and Pearson correlation distance metrics on rows and columns, respectively.](pr.117.014944f6){#F6}

We would expect patients with more aggressive forms of brain cancer to express higher levels of the 20 genes if the tumor cells relied on expression of these genes to survive. To test this hypothesis, we downloaded normalized log2 RSEM gene expression values for GBM and low-grade glioma (LGG) patients as a combined cohort (GBMLGG) from GDAC Firehose to evaluate differences in expression. Of the 20 genes, 11 had significantly higher expression in GBM patients versus LGG patients using a Kruskal-Wallis test (*P* \< 0.05) ([Supplemental Fig. 3](http://pharmrev.aspetjournals.org/lookup/suppl/doi:10.1124/pr.117.014944/-/DC1)). Interestingly two genes, *BOC* and *VEGFC*, showed no significant difference in expression between diseases, and both have been implicated in brain tumor progression. *FDCSP* was not expressed in the majority of patients and could not be evaluated. The remaining six genes had significantly increased expression in LGG and indicate an interesting contrast between diseases that may warrant further investigation.

Further validation of the proteins identified in [Table 2](#T2){ref-type="table"} was performed with the open-access resource Pharos ([@B146]) ([Supplemental Table 2](http://pharmrev.aspetjournals.org/lookup/suppl/doi:10.1124/pr.117.014944/-/DC1)). The majority of the identified genes (12) had Tbio classifications while two (ESR2 and TH) had Tclin classifications and three (ELOVL6, FURIN, GZMB) were assigned a Tchem classification. All targets that were mapped to GTEx expression were classified as having high or medium expression levels in normal brain tissue. From the analysis, 21 out of 25 genes in [Fig. 4](#F4){ref-type="fig"} and 12 out of 20 genes in [Table 2](#T2){ref-type="table"} have a known link to brain cancer. Of the 12 genes, seven are linked to GBM: *BOC*, *ELOVL6*, *IRX3*, *LITAF*, *NDEL1*, *PTPRN*, and *QSOX1*. Furthermore, ELOVL6 small molecule probes have been identified and could be used to validate ELOVL6 as a drug target. Given that ELOVL6, ESR2, TH, FURIN, and GZMB have probes or inhibitors identified, these proteins could be a starting point for validation of our TCGA data mining.

We expanded our analysis of the 20 genes to include 33 TCGA diseases ([Fig. 7](#F7){ref-type="fig"}). Head and neck squamous cancer had the highest average expression of the 20 genes in the analyzed patient samples. In addition, several genes were identified that have consistently higher expression in several cancers. For example, *PTPRN* was highly expressed in pancreatic adenocarcinoma and the pheochromocytoma and paraganglioma cohort, and therefore, those cancer subsets may be more sensitive to targeted PTPRN therapy. Several of the genes are involved in the transcriptional regulation of EGFR, including *ESR2*, *EREG*, and *VEGFC*. In addition, several genes are indirectly involved in EGFR regulation, including *FUT8*, *LITAF*, *FURIN*, *NKX3-1*, and *TH*. Upon further validation, these transcription factors may prove to be relevant to the progression and recurrence of GBM.

![Expression of 20 genes significantly associated with reduced survivability in GBM is shown across 33 TCGA diseases. Gene expression from each patient sample was converted to a *z*-score, and *z*-scores were recalculated across all diseases for each gene to show relative expression. Regions of the heatmap are circled to highlight genes with consistent higher expression (10th percentile \>0.5) and previously published support for relevance to disease progression (cyan) or high expression without previously published support for disease progression (purple). Diseases are ranked by decreasing average expression and ribbon on the right is colored to indicate average expression per patient sample.](pr.117.014944f7){#F7}

Below, we briefly summarize the 20 genes significantly associated with reduced survivability and discuss current research on the link between each gene and cancer. Further validation of each target is necessary to confirm the importance of each gene in the context of GBM. Inhibiting the activity or expression of one, or a combination, of the proteins discussed below may prove to be a viable treatment strategy for GBM.

#### a. BOC cell adhesion associated, oncogene regulated (BOC) {#s9}

BOC is a member of the immunoglobulin/fibronectin type III repeat family and promotes myogenic differentiation. During oncogenesis, BOC promotes hedgehog pathway signaling by sustaining a feedback mechanism that enhances the concentration of Sonic hedgehog (Shh) ligand ([@B217]). The hedgehog signaling pathway is necessary for normal cellular processes such as embryogenesis and growth of hair follicles and taste papillae in adults ([@B181]). In the absence of the Shh ligand, the GPCR Ptch is active, which blocks Smo signaling. When Shh ligand is present, it inactivates Ptch, allowing Smo to signal transcription of target genes. Since BOC activates hedgehog pathway signaling, it likely contributes to GBM progression and may be a potential drug target. In our analysis, increased *BOC* expression is strongly associated with poor overall survival (*P* = 1.36 × 10^−6^). This is the first report, to our knowledge, of *BOC* associated with GBM.

#### b. C-Type lectin domain family 4 member G pseudogene 1 (CLEC4GP1) {#s10}

CLEC4G is a 32.6-kDa membrane-bound protein expressed in the liver and lymph nodes and plays a role in T-cell immune response. TCGA whole-genome sequencing revealed *CLEC4G* was downregulated in hepatocellular carcinoma tissue ([@B87]). As a pseudogene, *CLEC4GP1* is likely a nonfunctional copy of the enzyme. Pseudogenes can arise during duplication if a mutation occurs in the DNA or with retrotransposition, in which the cDNA product of the reverse-transcribed mRNA becomes incorporated in the genome. In our analysis, increased *CLEC4GP1* expression is strongly associated with poor overall survival (*P* = 2.63 × 10^−5^). *CLEC4GP1* is located on chromosome 19. In one study, *CLEC4GP1* mRNA expression increased in response to an mRNA-based vaccine encoding influenza A hemagglutinin from a pandemic strain ([@B47]). Additionally, expression of *CLEC4GP1* is high in samples from patients diagnosed with adenoid cystic carcinoma ([Fig. 7](#F7){ref-type="fig"}).

#### c. ELOVL fatty acid elongase 6 (ELOVL6) {#s11}

ELOVL6 is highly expressed in the brain, and the gene is often hypomethylated in GBM ([@B230]). This enzyme performs the first and rate-limiting step of fatty acid elongation, with malonyl-CoA as a 2-carbon donor and is important for insulin sensitivity and energy metabolism ([@B135]). Phospholipids containing longer acyl chains are abundant in cancer tissue, and ELOVL6 is the main enzyme responsible for fatty acid elongation in cancer ([@B131]). The gene is located on chromosome 4q25, adjacent to the *EGF* gene. Expression of *ELOVL6* may be high because it shares an enhancer region with *EGF*. Enhancers perform complex functions and can activate transcription of specific genes upstream or downstream by engaging the transcriptional machinery. In acute myeloid leukemia, a novel chromosomal rearrangement was found to activate *ELOVL6* and *EGF* ([@B7]). ELOVL6 has been studied in the context of many cancers. Increased *ELOVL6* mRNA expression was found in triple-negative breast cancer tissue ([@B252]). Additionally, ELOVL6 and lipid composition may be regulated by the RB-E2F transcription factor 1 pathway ([@B144]). An ELOVL6 inhibitor, Compound A, inhibited tumor growth in an in vivo model of squamous cell carcinoma ([@B131]), and therefore validation and pursuit of ELOVL6 inhibition in GBM is warranted.

#### d. Epiregulin (EREG) {#s12}

EREG is a 19-kDa peptide hormone that acts as a ligand for the EGF receptor and ErbB4. When cleaved by a disintegrin and metalloproteinase (ADAM) enzyme from the transmembrane pro-peptide to an active soluble form, EREG binds EGFR family members and initiates the signaling cascade. *EREG* expression is upregulated in gastric ([@B244]), colon ([@B244]), lung ([@B207]), and head and neck ([@B194]) cancers, among others. In a colon cancer xenograft model, *EREG* expression correlated with a positive response to the anti-EGFR monoclonal antibody cetuximab, suggesting the tumors were dependent on the EGFR signaling pathway activated by EREG ([@B98]). *EREG* transcription is regulated by insulin, Sp1, NF-*κ*B, and AP-2 ([@B117]; [@B154]; [@B155]). Silencing of *EREG* in a breast cancer cell line inhibited metastasis, angiogenesis, and tumor cell extravasation ([@B75]). EREG is a partial agonist of EGFR dimerization and induces differentiation in breast cancer cells ([@B54]). The emerging role for EREG as a key activator of EGFR signaling driving cancer cell proliferation suggests that inhibition of EREG binding to EGFR is a potential targeted cancer treatment. In our analysis, *EREG* expression was associated with poor overall survival in GBM patients (*P* = 5.6 × 10^−5^). High *EREG* expression was also found in TCGA samples from patients diagnosed with rectal adenocarcinoma ([Fig. 7](#F7){ref-type="fig"}). Furthermore, EREG activates the extracellular signaling-related kinase/MAPK pathway in GBM, suggesting inhibition of the EREG-EGFR interaction may be a strategy for EREG-overexpressing GBM patients ([@B112]).

#### e. Estrogen receptor 2 (ESR2) {#s13}

*ESR2* encodes the gene for estrogen receptor *β* (ER*β*), a nuclear hormone receptor for estrogen, is considered a tumor suppressor in the context of GBM and other cancers ([@B159]; [@B188]), and enhances chemosensitivity in NSCLC ([@B147]). Treatment with ER*β* agonist, LY500307, is efficacious in a GBM tumor-bearing mouse model ([@B188]). Additionally, ER*β* expression, analyzed immunohistochemically, declines as brain astrocytic tumors progress ([@B16]). In our analysis, increased *ESR2* expression is strongly associated with poor overall survival (*P* = 1.68 × 10^−4^), which is in contrast with the tumor suppressing effects of the protein. Furthermore, expression of *ESR2* is high in TCGA samples from patients diagnosed with diffuse large B-cell lymphoma ([Fig. 7](#F7){ref-type="fig"}). The tumor-suppressing characteristics of ESR*β* may prevent it from being a potential anticancer target.

#### f. Follicular dendritic cell secreted protein (FDCSP) {#s14}

FDCSP (C4orf7) is a 9.7-kDa peptide that promotes invasion and metastasis of tumor cells. Although relatively little is known about this peptide, overexpression of FDCSP is common in tumorigenesis, especially in ovarian cancer ([@B232]). FDCSP expression has also been implicated as a marker of follicular dendritic cell sarcoma ([@B122]). The position, on chromosome 4q13, and characteristics, including amino acid composition, molecular mass, and isoelectric point, suggest FDCSP may be similar to the inflammatory C-X-C chemokines, such as interleukin-8 ([@B132]). In our analysis, increased *FDCSP* expression is strongly associated with poor overall survival (*P* = 1.24 × 10^−4^). *FDCSP* expression may be important for GBM progression.

#### g. Furin {#s15}

Furin is a protease that activates matrix metalloproteinases, including proparathyroid hormone, transforming growth factor beta 1 precursor, proalbumin, pro-beta-secretase, membrane type-1 matrix metalloproteinase, beta subunit of pro-nerve growth factor, and von Willebrand factor. Furin is linked with tumor progression in several cancers, including head and neck squamous cell carcinoma, breast cancer, and rhabdomyosarcoma ([@B97]). In astrocytoma cells, inhibition of furin decreases cell proliferation and invasiveness ([@B138]). Furthermore, furin promotes activation of pro-TGF*β*1 and pro-TGF*β*2, demonstrating a tumorigenic role in glioma-initiating cells ([@B226]). In our analysis, increased furin expression is strongly associated with poor overall survival (*P* = 1.79 × 10^−4^). Transcription of furin is promoted by AP-1 (activator protein-1), c-Jun, and ATF-2. Proteolysis is important in cancer, and furin activates several enzymes via proteolysis that contribute to cell migration and survival, including protein kinase C ([@B184]). Combined inhibition of furin, ADAM, calpain, and another serine protease is necessary to prevent glioma migration and slow growth mediated by protein tyrosine phosphatase *μ* ([@B165]). Inhibitors of furin demonstrate antiproliferative effects and are being optimized in the context of inhibition of viral replication ([@B37]; [@B127]). The extensive evidence of the tumorigenic role of furin in several cancers, including brain cancer, suggests it may be a promising therapeutic target, and inhibitors of furin may improve treatment outcomes.

#### h. Fucosyltransferase 8 antisense RNA 1 (FUT8-AS1) {#s16}

FUT8 is a 66.5-kDa enzyme located in the Golgi apparatus and extracellular space and catalyzes the transfer of fucose from GDP-fucose to N-linked type complex glycopeptides. Fucosylation is an important posttranslational glycosylation event that regulates cancer signaling processes including metastasis and epithelial-to-mesenchymal transition. The expression of *FUT8*-*AS1* suggests *FUT8* expression may be downregulated in GBM patients. In our analysis, increased *FUT8*-*AS1* expression is strongly associated with poor overall survival (*P* = 8.6 × 10^−5^). FUT8 function has been studied in the context of several cancers. For example, knockdown of FUT8 halted growth of in vitro and in vivo models of lung cancer ([@B27]). Additionally, inhibitors have been developed that block fucosylation in models of cancer ([@B149]). Although FUT8 expression has been studied in the context of lung, liver, colon, and other cancers, it has not been evaluated in GBM.

#### i. Granzyme B (GZMB) {#s17}

GZMB is a serine protease in the peptidase S1 family and is involved in mediating apoptosis. This enzyme cleaves after aspartate and plays a role in the cellular caspase cascade that leads to apoptosis. GZMB is the most abundant enzyme in cytotoxic granules responsible for the clearance of tumor cells, as well as cells infected with intracellular pathogens and allogeneic cells ([@B33]; [@B36]). It is also a prognostic marker in colorectal cancer ([@B168]). In our analysis, increased *GZMB* expression is strongly associated with poor overall survival (*P* = 5.29 × 10^−7^). Additionally, there is high expression of *GZMB* in TCGA samples from patients diagnosed with diffuse large B-cell lymphoma ([Fig. 7](#F7){ref-type="fig"}). *GZMB* transcription is regulated by nuclear factor of activated T cells, Ikaros, and AP-1 ([@B234]). *GZMB* gene transcription is also activated and enhanced by NF-*κ*B, which binds approximately 10 kb downstream from the *GZMB* transcription start site ([@B92]), and by Janus kinase 1/signal transducer and activator of transcription signaling ([@B99]). The role of GZMB in apoptosis makes it an attractive anticancer target.

#### j. Iroquois homeobox 3 (IRX3) {#s18}

IRX3 is a 5.2-kDa transcription factor in the Iroquois homeobox family of developmental factors and is involved in Shh-dependent neural patterning. IRX3 belongs to class I proteins of neural progenitor factors and is repressed by Shh signals. IRX3 contains transcription factor binding sites for ER*α*, Pax-5, AP-2*α*, AP-2*β*, AP-2*γ*, FOXD1, and C/EBP, among others. In our analysis, increased *IRX3* expression is strongly associated with poor overall survival (*P* = 1.15 × 10^−4^). In addition, consistently higher expression of *IRX3* is observed in TCGA samples from patients diagnosed with breast cancer ([Fig. 7](#F7){ref-type="fig"}). *IRX3* is a target gene of *WHSC1L1* (Wolf-Hirschhorn syndrome candidate 1-like 1 gene, or NSD3), a known oncogene in breast cancer, and may be a regulator of WNT signaling ([@B255]). DNA methylation profiling of an oligodendroma-derived cell line revealed hypermethylation of the CpG island on an *IRX3* exon, consistent with overexpression of *IRX3* in tumor tissue compared with normal brain samples ([@B152]). Although IRX transcription factors have been identified in multiple genome-wide sequencing studies in cancer, they specifically hamper the tumor-suppressing activity of the TGF-*β* pathway ([@B133]). Therefore, blocking *IRX3* expression or inhibiting its ability to suppress the TGF-*β* pathway may be an option for GBM treatment.

#### k. Lipopolysaccharide-induced tissue-necrosis-factor factor (LITAF) {#s19}

LITAF is a lipopolysaccharide-regulated transcription factor located on chromosome 16 that regulates VEGF and plays a role in angiogenesis and inflammatory response ([@B213]). LITAF contains a small integral membrane protein of lysosome/late endosome-like domain with a YXX *ϕ* motif that mediates transport of membrane proteins to and from the endosome, Golgi apparatus, and lysosomes. In several cancers, LITAF induces inflammation and promotes cancer cell survival. Stimulation by lipopolysaccharide causes LITAF to translocate from the cytoplasm with its partner protein STAT6(B) to the nucleus to promote gene expression ([@B265]). In our analysis, increased *LITAF* expression is strongly associated with poor overall survival (*P* = 2.3 × 10^−5^). Furthermore, *LITAF* was in the top 30 overexpressed genes in GBM in a large-scale expression analysis study ([@B42]). Therefore, blocking the LITAF-STAT6(B) protein-protein interaction may be a viable treatment strategy. However, LITAF possesses a tumor-suppressing role in pancreatic cancer ([@B262]), and its expression can be induced by P53 ([@B212]). *LITAF* knockdown promoted tumor malignancy and growth in nude mice injected subcutaneously with prostate cancer cells ([@B260]). Overall, LITAF plays a complex role in the progression of cancer.

#### l. NudE neurodevelopment protein 1 like 1 (NDEL1) {#s20}

NDEL1 is a 38-kDa cytoskeletal protein that contains an N-terminal coiled coil NUDE domain and is important for the regulation of microtubule organization to promote neuronal migration. Expression of NDEL1 is highest during mitosis, and it is necessary for mitotic cell division ([@B221]). In our analysis, increased *NDEL1* expression is strongly associated with poor overall survival (*P* = 5.7 × 10^−5^), and consistently higher expression is found in acute myeloid leukemia ([Fig. 7](#F7){ref-type="fig"}). NDEL1 has also been implicated in the development of schizophrenia via its protein-protein interactions with Disrupted-in-Schizophrenia 1 (DISC1) ([@B80]). NDEL1 associates with microtubules, dynein, CENPF, and ZNF365. Additionally, the *NDEL1* gene contains P53, c-myc, and ARP-1 transcription factor binding sites. With an increased understanding of the role of NDEL1 in cancer migration, effective, targeted inhibitors could be developed to control tumor growth.

#### m. NK3 homeobox 1 (NKX3-1) {#s21}

NKX3-1 is a transcription factor that negatively regulates epithelial cell growth in prostate tissue. Loss of *NKX3-1* is common in prostate cancer patients ([@B81]; [@B20]). NKX3-1 negatively regulates the PI3K-AKT pathway to suppress tumor growth, and heterozygous deletions of *NKX3-1* and *PTEN* cause prostate adenocarcinomas in mice ([@B2]). Additionally, NKX3-1 functions as a tumor suppressor in hepatocellular carcinoma ([@B101]). In our analysis, increased *NKX3-1* expression is strongly associated with poor overall survival (*P* = 1.74 × 10^−4^), and consistently higher expression is also found in prostate adenocarcinoma ([Fig. 7](#F7){ref-type="fig"}). To our knowledge, NKX3-1 has not yet been studied in the context of GBM.

#### n. Podocan like 1 (PODNL1) {#s22}

PODNL1 is an extracellular protein expressed in tibial nerves, coronary arteries, and bone marrow mesenchymal stem cells and is involved in proteinaceous extracellular matrix formation. It belongs to the small leucine-rich proteoglycan (SLRP) family of 17 genes and is a member of Class V SLRPs, residing on chromosome 19q. SLRPs also act upstream of signaling cascades, including receptor tyrosine kinases like ErbB family members ([@B189]). Interestingly, the Class V SLRPs bind collagen I and inhibit cell growth by inducing cyclin-dependent kinase inhibitor 1 expression ([@B196]). Additionally, another SLRP family member, decorin, binds to EGFR and lowers receptor levels by caveolin-mediated internalization ([@B264]; [@B192]; [@B123]). High expression of PODNL1 correlates with poor prognosis in ovarian cancer ([@B216]). Methylation of the *PODNL1* gene may be important for phenotypic changes that occur during aging ([@B86]), and *PODNL1* expression is associated with high-grade glioma ([@B253]). Our analysis supports these findings; increased *PODNL1* expression is strongly associated with poor overall survival (*P* = 3.61 × 10^−6^). Because several proteins in the SLRP family play a role in cancer progression, PODNL1 may have an important function as well.

#### o. Protein tyrosine phosphatase, receptor type N (PTPRN) {#s23}

*PTPRN* (also known as islet antigen-2 or IA-2) is a gene encoding a 105.8-kDa protein in the protein tyrosine phosphatase family responsible for signaling processes related to cell growth, differentiation, and oncogenic transformation. Hypermethylation of *PTPRN* in ovarian cancer patients was associated with shorter survival ([@B17]). It was initially discovered as a gene differentially expressed in human pancreatic beta islet cells and is localized on the plasma membrane and in endosomes. *PTPRN* depletion reduced small cell lung cancer cell growth ([@B249]). Valproic acid induced the expression of *PTPRN* as a result of increased acetylation in the promoter region ([@B241]). Analysis of TCGA samples from patients with pancreatic adenocarcinoma, pheochromocytoma, paraganglioma, GBM, and LGG revealed consistently higher expression of *PTPRN* ([Fig. 7](#F7){ref-type="fig"}). In our analysis, increased *PTPRN* expression is strongly associated with poor overall survival (*P* = 2.19 × 10^−5^). Although PTP family proteins have been well studied in the context of cancer, little work has been done to elucidate the role of PTPRN in brain cancer.

#### p. Quiescin sulfhydryl oxidase 1 (QSOX1) {#s24}

QSOX1 is a flavin adenine dinucleotide-dependent 82.6-kDa enzyme that forms disulfide bonds in proteins by oxidizing sulfhydryl groups. It is found in the extracellular space, Golgi apparatus, and endoplasmic reticulum, where it functions alongside protein disulfide isomerase to fold nascent proteins ([@B89]). QSOX1 contains one thioredoxin domain and one ERV/ALR sulfhydryl oxidase domain. In pancreatic cancer, *QSOX1* expression correlates with cell migration and survival, and QSOX1-mediated migration of pancreatic ductal carcinoma cells may be activated by MMP-2 and MMP-9 ([@B108]). Interestingly, loss of *NKX3-1* expression correlates with an increase in *QSOX1* expression in prostate cancer ([@B202]). In our analysis, increased *QSOX1* expression is strongly associated with poor overall survival (*P* = 1.96 × 10^−8^). Proteomic analysis using iTRAQ identified that QSOX1 expression was upregulated in hepatocellular carcinoma ([@B73]). Furthermore, knockdown of QSOX1 sensitizes nasopharyngeal carcinoma cells to radiation ([@B261]). Ebselen, a covalent inhibitor of QSOX1, suppressed pancreatic tumor growth in vivo ([@B78]). Much work has been done to elucidate the complex role of QSOX1 in several cancers, and it clearly plays an important role in disease progression.

#### q. Semaphorin 4F (SEMA4F) {#s25}

SEMA4F is a membrane-bound glycoprotein in the semaphorin family of receptors. Semaphorins are involved in eliciting intracellular signaling cascades and may be receptors for EGFR signaling ligands. Therefore, semaphorins are important regulators of tumor growth, angiogenesis, migration, and apoptosis ([@B25]). For example, SEMA3B was found to be a marker for poor survival in patients over 50 diagnosed with GBM ([@B179]). In contrast, SEMA4D can stimulate or inhibit breast cancer cell migration and adhesion, depending on the presence of receptor tyrosine kinases ERBB2 and MET ([@B209]). In our analysis, increased *SEMA4F* expression is strongly associated with poor overall survival (*P* = 3.24 × 10^−9^). SEMA4F is linked to the induction of prostate cancer neurogenesis ([@B9]) and may be important for breast cancer progression ([@B60]). SEMA4F knockdown was linked to Schwann cell proliferation in the development of neurofibroma downstream of the loss of NF1 tumor suppressor function ([@B158]). The molecular mechanisms driving the function of this signaling receptor in cancer are complex.

#### r. Tyrosine hydroxylase (TH) {#s26}

TH, as its name suggests, hydroxylates tyrosine to form the precursor for dopamine, [l]{.smallcaps}-dopa, and is induced by hypoxic stress via HIF1*α*, common in the tumor microenvironment. TH is also a marker for neurons containing downstream products dopamine, norepinephrine, and epinephrine. In our analysis, increased *TH* expression is strongly associated with poor overall survival (*P* = 4.62 × 10^−5^). *TH* gene expression is also significantly increased in pheochromocytoma and paraganglioma ([Fig. 7](#F7){ref-type="fig"}). To date, eight inhibitors of TH have been studied. One of the inhibitors, alpha-methyl-p-tyrosine, was used to treat pheochromocytoma; however, use was discontinued because of severe side effects. In general, inhibition of TH may rely on a small therapeutic window for safe usage, because of the crucial role of the enzyme in dopamine synthesis.

#### s. Vascular endothelial growth factor C (VEGFC) {#s27}

VEGFC is a dimeric, secreted growth factor in the VEGF (vascular endothelial growth factor) family. The VEGF family contains five members, VEGFA, placenta growth factor, VEGFB, VEGFC, and VEGFD, and acts by binding tyrosine kinase VEGF receptors on the cell surface. VEGFC binds and activates VEGFR-2 and VEGFR-3. VEGFC is overexpressed in peripheral blood mononuclear cells and plays an important role in lymphoangiogenesis ([@B128]). *VEGFC* is also strongly overexpressed in patients with thyroid cancer ([Fig. 7](#F7){ref-type="fig"}). Furthermore, VEGFC expression is upregulated in brain tumors including GBM and hemangioblastomas, suggesting this protein is important for tumor-associated inflammation ([@B100]). In our analysis, increased *VEGFC* expression is strongly associated with poor overall survival (*P* = 7.08 × 10^−7^). Expression of *VEGFC* is associated with poor overall survival in GBM (*P* \< 0.001 and *P* = 0.023) ([@B250]; [@B259]). VEGFC is targeted by microRNA-144 and microRNA-186 to halt tumor growth in cervical and bladder cancer, respectively ([@B82]; [@B214]). High expression of this protein in GBM suggests VEGFR-3 plays a vital role in cancer proliferation, potentially as much as VEGFR-1. CS2164 is a novel multikinase inhibitor that targets VEGFR-1, VEGFR-2, VEGFR-3, PDGFR alpha, c-Kit, Aurora kinase b, and CSF-R1 and exhibited antitumor potency in mouse xenograft models of colon, lung, liver, and stomach cancer ([@B263]). Inhibitors of VEGFR-1 or VEGFR-3, or inhibitors of the maturation of VEGFC, could be efficacious in GBM, based on the strong correlation between poor prognosis in several cancers and VEGFC expression.

#### t. Chromosome 20 open reading frame 166 antisense RNA 1 (C20orf166AS1) {#s28}

*C20orf166AS1* is an 8.5-kb- long noncoding RNA (lncRNA). *C20orf166AS1* was reported as a prostate-cancer-specific lncRNA that was negatively correlated with prostate cancer ([@B91]). Analysis of TCGA samples supports these findings; *C20orf166AS1* expression is consistently higher in prostate adenocarcinoma patient samples than in normal tissue ([Fig. 7](#F7){ref-type="fig"}). In our analysis, increased *C20orf166AS1* expression is strongly associated with poor overall survival (*P* = 3.6 × 10^−7^). Aside from its possible role in prostate cancer, *C20orf166AS1* function has not been fully elucidated.

### 2. Protein Targets Identified via Proteomic Approaches {#s29}

Although the application of modern proteomic approaches has yet to reach its full potential in GBM research, several important studies have identified potential drug targets. Traditionally, proteomics have been performed with 2DGE and mass spectrometry. Although useful, 2DGE has several major limitations. For example, 2DGE cannot detect low abundance proteins, proteins with a molecular mass greater than 100 kDa, or hydrophobic membrane proteins ([@B77]). In addition, proteins with isoelectric point values outside the pH range go undetected, including important GBM proteins such as EGFR and VEGFR ([@B96]). Proteomic technologies have overcome these challenges with several methods, namely targeted mass spectrometry via SRM (selected reaction monitoring), iTRAQ, and SWATH-MS (sequential window acquisition of all theoretical mass spectra). Here we discuss several preclinical protein targets involved in GBM identified via proteomic approaches.

Several GBM proteomic studies have identified annexin A2 as a possible drug target ([@B167]; [@B134]; [@B257]). Annexin A2 is a calcium-binding cytoskeletal protein expressed in cancer cells and is strongly correlated with tumor aggression, metastasis, and glioma patient survival ([@B136]). The protein aids the conversion of plasminogen to plasmin, a serine protease that activates metalloproteinases and degrades the extracellular matrix to promote cell metastasis ([@B76]). Consistent overexpression of annexin A2 emphasizes its role in various subtypes of GBM. Thus, annexin A2 may be a promising drug target. Small molecule annexin A2 inhibitors have been developed to prevent human papilloma virus ([@B177]; [@B242]). Further validation of annexin A2 inhibitors in models of GBM is warranted.

One study identified nine potential GBM targets by comparing microarray data sets of neural stem cells and GBM stem cells and further validating the findings with RT-PCR and Western blot ([@B203]). Nine overexpressed proteins, PBK, CENPA, KIF15, DEPDC1, CDC6, DLG7, KIF18A, EZH2, and HMMR, correlated with poor patient survival and are potential GBM drug targets. CENPA was further validated as a potential target in GBM-initiating cells ([@B18]). PBK is a MAPKK involved in p38-mediated cell motility and DNA damage response ([@B10]) and has been validated in vivo as a GBM target ([@B104]). EZH2 has also been validated as a target in GBM, and overexpression is associated with poor prognosis ([@B70]; [@B258]). CDC6, a gene involved in the RB/E2F pathway, was associated with decreased astrocytic glioma patient survival ([@B52]). Additionally, HMMR was validated as a potential target for GBM stem cell inhibition ([@B219]). The other proteins have not been validated further in the context of GBM but may also represent potential drug targets.

Proteomic approaches may also explain potential reasons for drug or target failure. To determine why antiangiogenic therapies failed, a proteomic approach based on selected reaction monitoring was employed on patient-derived intracranial GBM xenografts in rodents ([@B38]). Levels of tricarboxylic acid cycle enzymes such as isocitrate dehydrogenase and aldehyde dehydrogenase decrease in response to antiangiogenic therapy, suggesting the cells evade death by increasing glycolysis ([@B38]). Additionally, a systems-based statistical analysis of a proteomic and transcriptomic signature of GBM was identified, concluding a strong link between GBM invasive properties and the TGF-*β* signaling pathways ([@B65]). Targeting these pathways may inhibit GBM proliferation; however, target validation is necessary to rule out proteins that do not drive tumor growth.

### 3. Target Validation {#s30}

Correlation between gene expression and patient survival does not necessarily indicate the gene (or protein) is critical for tumor progression or a viable drug target. For example, tyrosine hydroxylase is required for the synthesis of dopamine, and inhibition of TH, at least by the reported inhibitors, showed significant adverse effects. Therefore, rigorous validation of the 20 genes determined from TCGA analysis is crucial to move forward and develop a viable treatment option for GBM.

Clinical trials often fail due to insufficient target validation in the preclinical stage of the drug discovery process. To validate each target appropriately, CRISPR-Cas9-mediated gene knockdown can be used to assess tumor growth in vitro and in vivo. Gene knockouts that significantly inhibit tumor growth would be pursued for druggability. High throughput small molecule binding screens of each target could be run using differential scanning fluorimetry or other binding determination methods. For targets with selective inhibitors, further validation can be performed. Although our TCGA analysis results demonstrate a potential direction for GBM drug discovery research, target validation is required before further effort is used to develop inhibitors of these targets.

C. Synthetic Lethality {#s31}
----------------------

GBM tumor heterogeneity will likely render single target inhibition ineffective. In general, combination therapies are necessary to halt tumor growth. A potential approach to identify synergistic interactions is to perform "synthetic lethal" screens. Synthetic lethality is the concept that a combination of two or more gene mutations or alterations is necessary for cell death, and the mutation or inhibition of only one of the genes allows tumor cells to survive ([@B235]). Synthetic lethal combinations can be identified via several strategies. For example, large, short hairpin RNA (shRNA) libraries can be used to screen cell lines with an inhibitor, that, when in combination with certain shRNAs, causes a lethal phenotype. Synthetic lethal pairs can also be discovered computationally by mining large datasets. By using this method, the known synthetic lethal relationship between *P53* and *PLK1* was validated by comparing patient survival data with pairs of genes in which the expression of one of the genes was underrepresented ([@B210]).

Several other synthetic lethal combinations have been identified in the context of GBM. Large-scale, shRNA library screening identified that the inhibition of *MYC*, *P38MAPK*, or *ERK* signaling pathways may be synthetically lethal with PI3K inhibitor PX-866 ([@B111]). EGFR inhibition is synthetically lethal with pharmacological stabilization of *P53* ([@B124]). *P53* mutations have also sensitized GBM cells to combined p-AKT inhibition and radiation by antagonizing DNA repair ([@B157]). Furthermore, *IDH1*-mutated gliomas are potentially more susceptible to BCL-xL inhibition than other gliomas ([@B107]). Continued work in this area is expected to generate novel effective treatment strategies for GBM.

D. Preclinical Models of Glioblastoma {#s32}
-------------------------------------

Preclinical in vivo models of GBM can recapitulate hallmarks of cancer, including tissue invasion, sustained angiogenesis, evasion of apoptosis, and cancer-specific metabolism that cannot be modeled in vitro. Robust models of GBM that mimic the human tumor microenvironment are needed to assess drug safety profiles and reduce clinical trial failure. There are three major types of preclinical GBM models: chemically induced models, xenograft models, and genetically engineered mouse models. Some of the current and state-of-the-art strategies for developing animal models of GBM will be summarized here. \[This subject has been reviewed extensively by [@B94], [@B140], and [@B191]\].

GBM mouse models have evolved in an attempt to mirror human tumor characteristics and microenvironment. One of the earliest models, the chemically induced GBM tumor, is generated by treating rats with *N*-nitroso compounds. The spontaneity of tumor generation in this model provides insight about the underlying molecular pathways involved in chemically induced mutagenesis. However, the rat tumors generally do not model human GBM histologic characteristics and cell lines suffer from genetic drift ([@B94]). Xenografts of human tumor cell lines injected into immunodeficient mice have also been used. However, these models can be difficult to establish and do not factor in immune response or changes in stromal environment ([@B94]). Therefore, GEMMs are excellent as in vivo GBM models because of the extensive molecular characterization of the human GBM tumor genome, which confirmed key mutations that drive oncogenesis. Compounds of interest can be tested on several variations of GEMMs, including those generated via combinations of *P53*, *PTEN*, *NF1*, *RB*, and PDGF alterations (reviewed in depth in [@B200]). GEMMs have also provided valuable insight on the cell of origin of GBM. For example, GBM tumors can form in mice with conditional tumor suppressor alleles of *NF1*, *P53*, and *PTEN* that are injected with cre recombinase-expressing adenovirus ([@B6]). The downsides of GEMMs are that they can be costly and time consuming and do not exhibit the heterogeneity of human GBM tumors. Additional in vivo models include orthotopic models, in which GBM cells are injected intracranially, and patient-derived xenograft models, in which primary patient tumors are cultured and implanted in mice subcutaneously ([@B240]). Furthermore, a Human Glioblastoma Cell Culture (HGCC) open resource has been organized to promote in vitro and in vivo testing ([@B247]). The HGCC resource contains a bank of 48 GBM cell lines derived from patients for translational research use. This bank allows robust in vivo representations of GBM to promote new discoveries. Numerous in vivo models of GBM exist, but none perfectly capture the complexity of tumor biology and microenvironment.

Because each GBM tumor model has its shortcomings, there remains a need for better preclinical models for compound screening. One strategy to meet this need involves avatar mice and coclinical models of GBM ([@B126]). The mouse avatar allows efficient testing of different treatment strategies by implanting GBM tumor tissue resected from the patient into mice with the goal of selecting a promising therapy for each individual patient ([@B126]). Unfortunately, grafted patient-derived xenograft tumors are altered by the mouse biology and do not predict response to treatment with great accuracy ([@B19]). CRISPR/Cas9 technology was previously used to generate *P53*, *PTEN*, and *NF1* gene deletions in mice ([@B266]). Although the CRIPSR/Cas9 system represents a more convenient model for in vivo tumor development, the need for an accurate model of GBM still exists. In general, in vivo models that mimic human intratumoral heterogeneity, tumor initiation, and tumor microenvironment are needed to accurately assess in vivo efficacy of a drug.

VI. Blood-Brain Barrier {#s33}
=======================

A. Characteristics of the Blood-Brain Barrier {#s35}
---------------------------------------------

The BBB is responsible for nutrient transport, homeostasis, and communication between the body and the brain and also prevents foreign substances from reaching the brain. Research on the BBB dates to the 1880s, when a barrier to the transport of solutes from the blood to the brain was discovered. Paul Ehlrich furthered BBB research with experiments demonstrating that passage into the brain of peripherally injected dyes was impeded. Small molecule permeability of the BBB is an important consideration for drug development. Not only does the BBB impede small molecule transport, but active BBB transporters clear foreign material that passes the protective layers. The BBB is a dynamic, flexible interface between the brain and the body.

The BBB is composed of a monolayer of endothelial, ependymal, and tanycytic cells held together by restrictive tight junctions ([Fig. 8](#F8){ref-type="fig"}). Two types of cellular junctions halt passive diffusion and prevent leakiness between the endothelial cells: intercellular adherens junctions and paracellular tight junctions. Adherens junctions are composed of vascular endothelium, cadherin, actinin, and catenin ([@B229]). Tight junctions consist of three major proteins: occludin, claudin, and junction adhesion molecules. Occludins are regulated by phosphorylation of serine, tyrosine, and threonine residues. Junction adhesion molecules regulate the formation of tight junctions during the acquisition of cell polarity ([@B46]). Furthermore, there are several other important cytoplasmic accessory proteins including zonula occludens and cingulin. Altogether, these proteins maintain the integrity of the BBB.

![The blood-brain barrier protects the brain from foreign material with a layer of endothelial cells bound by adherens junctions \[i.e., vascular endothelial (VE)-cadherin\] and tight junctions \[i.e., junction adhesion molecules (JAMs), endothelial cell adhesion molecule (ESAM), claudins, and occludins\].](pr.117.014944f8){#F8}

Nutrients and small molecules may be transported in and out of the brain by various methods, including passive diffusion, carrier-mediated transport, endocytosis, and active transport. Small biomolecules, such as water and various lipid-soluble molecules, are transported by passive diffusion. Typically, small lipophilic compounds will diffuse through the BBB; however, these properties make compounds more likely to be P-glycoprotein (Pgp) substrates or be taken up by peripheral tissues ([@B12]). Thus, although lower molecular mass and ClogP values are often optimal in theory for CNS drug discovery, the determination of appropriate values is a balancing act. Carrier-mediated transport is driven by two major protein families, the solute carrier (SLC) superfamily and ATP binding cassette (ABC) transporters. The main function of these transporters is to carry essential amino acids and glucose from the blood to the brain. Carrier-mediated transport may be hijacked by drug delivery. For example, System L has a broad substrate specificity for large molecules and, therefore, can transport levodopa ([@B148]; [@B34]). Endocytosis imports nutrients such as insulin via the formation of intracellular transport vesicles ([@B44]). Active transport requires energy in the form of ATP hydrolysis; the *µ*-opioid agonist fentanyl is likely taken up into the brain via active transport mechanisms ([@B85]). However, due to the complexity of the BBB neovascular unit, drug uptake and efflux likely proceed via multiple transport pathways.

The BBB poses several challenges for effective drug discovery. One challenge is reaching and maintaining effective CNS permeation and drug concentration. The brain uses efflux pumps at the luminal side of the BBB to recognize and remove foreign substances. In particular, ABC transporters prevent a large influx of lipophilic molecules, xenobiotics, toxic metabolites, and drugs ([@B53]). CNS tumors compromise the structural integrity of the BBB, causing it to be leaky at the tumor core ([@B26]). Although this may suggest that small molecules may be more permeable at the tumor site, the BBB surrounding the proliferating cells at the tumor's edge remains intact ([@B224]). Thus, BBB physiology and compound permeability are critical considerations for the CNS drug discovery process.

BBB transporters may provide an opportunity for the pursuit of alternative drug targets. [l]{.smallcaps}-dopa, melphalan, baclofen, and gabapentin are examples of drugs that cross the BBB via neutral amino acid transporters. Organic cation-carnitine transporters are used by verapamil, levofloxacin, and cephaloridine ([@B13]). Generally, compounds that use these transporters are similar in size and shape to the endogenous substrate of the protein. Additionally, uptake and efflux transporters can be inhibited by saturating the transporters. For example, saturating the large neutral amino acid transporter with large neural amino acids competes off the excess branched chain amino acids that enter the brain and cause neurotoxicity in maple syrup urine disease. Furthermore, a recent study demonstrated that metastasizing cells may signal to break down the BBB with microRNA-181c, allowing the cells to propagate in the brain ([@B116]). As a whole, successful drug discovery and development will involve efficient and reliable drug delivery methods to significantly improve treatment.

B. Blood-Brain Barrier Computational Modeling for Drug Discovery {#s36}
----------------------------------------------------------------

[@B119] developed a groundbreaking method of screening for orally bioavailable, drug-like molecules by using physicochemical properties known as the "rule of five." Traditional CNS drugs are biased toward targeting monoamine GPCRs, transporters, and ion channels. Therefore, an assessment of the physicochemical properties of CNS drugs would conclude that CNS drugs should be small lipophilic compounds. Generally, CNS drugs are smaller and more lipophilic than oral non-CNS drugs and have fewer hydrogen bond donors and a lower topological polar surface area ([@B64]). However, with increasing drug discovery efforts focused on nontraditional CNS targets, understanding of CNS-penetrant compounds could expand. To ameliorate this problem, a CNS multiparameter optimization (CNS MPO) algorithm was designed by Pfizer scientists with the goal of streamlining the CNS drug discovery process ([@B231]). The CNS MPO algorithm involves six physicochemical parameters \[lipophilicity (ClogP), distribution at pH = 7.4 (ClogD), molecular mass, topical polar surface area (TPSA), p*K*~a~ (of the most basic center), and the number of hydrogen bond donors (HBD)\] relative to CNS penetration and success. The value of each parameter is weighted (0 to 1) based on the probability of the compound crossing the BBB (0 = low probability; 1 = high probability). For example, it is well known that a compound with a ClogP value less than 0 will be less likely to cross the BBB, therefore a compound with a ClogP value less than zero would receive a 0 for the ClogP parameter. The total CNS MPO desirability score is the summation of the weighted scores based on each of the six properties, with a range from 0 to 6. An analysis of FDA-approved CNS drugs demonstrated 74% have a CNS MPO desirability score ≥4 ([@B231]). To assess the BBB permeability of novel GBM clinical candidates, we applied the algorithm to 73 of the small molecule compounds currently undergoing clinical trials related to GBM treatment.

We determined the CNS desirability score for 73 of the GBM drug candidates reported in [Table 1](#T1){ref-type="table"}, using the CNS MPO.v2 algorithm ([Fig. 9A](#F9){ref-type="fig"}) ([@B172]). The CNS MPO.v2 desirability score weighs five important CNS physicochemical properties, molecular mass, lipophilicity (ClogP), number of hydrogen bond donors, topical polar surface area, and p*K*~a~ (of the most basic center), from 0 to 1. These properties were calculated with ADMET Predictor Version 8. The desirability score was the summation of the weighted score of each component, with the number of HBD score doubled. The HBD value was found to correlate strongly with BBB permeability, whereas ClogD, a variable used in the original equation, was somewhat redundant to ClogP and removed ([@B172]). Interestingly, only 37% of the small molecule candidates in clinical trials currently have a score ≥4, a much lower percentage than the 74% of FDA-approved CNS drugs. This may highlight the significance of emphasizing BBB permeability in early-stage drug discovery and may explain future clinical trial failures (or highlights the use of novel drug delivery methods). The compound that scored highest, LB100 with a 5.68 out of 6, is a protein phosphatase 2A inhibitor. All scores of tested compounds are listed in [Supplemental Table 5](http://pharmrev.aspetjournals.org/lookup/suppl/doi:10.1124/pr.117.014944/-/DC1). Compounds with a desirable molecular mass (score = 1) made up 23% of the group, whereas an almost equal amount (25%) had higher-than-optimal molecular mass values, over 500 Da ([Fig. 9B](#F9){ref-type="fig"}). Most of the compounds (48%) had a ClogP score of 1 ([Fig. 9C](#F9){ref-type="fig"}). A large portion of the compounds had a favorable topical polar surface area (45% between 40 and 90 Å^2^; [Fig. 9D](#F9){ref-type="fig"}). Several of the compounds had an appropriate number of hydrogen bond donors as well (36% with scores \>0.8; [Fig. 9E](#F9){ref-type="fig"}). The majority of the compounds (64%) had a p*K*~a~ desirability score of 1 (p*K*~a~ \< 8 for the most basic center) ([Fig. 9F](#F9){ref-type="fig"}). Use of this CNS MPO algorithm together with other useful tools for predicting biologic behavior of small molecules could enhance and accelerate the drug discovery process.

![CNS MPO Version 2 scores were calculated for 73 of the GBM drug candidates listed in [Table 1](#T1){ref-type="table"}. Plots are shown for scores calculated for total CNS MPO score (A), molecular weight distribution (B), LogP value distribution (C), polar surface area value distribution (D), hydrogen bond donor total distribution (E), and p*K*~a~ value (of the most basic center) distribution (F).](pr.117.014944f9){#F9}

VII. Drug Discovery Challenges in GBM {#s37}
=====================================

CNS drugs typically have a lower FDA-approval rate than non-CNS drugs. Additionally, oncology drug discovery attrition rates are characteristically high, second only to the therapeutic area of woman's health ([@B113]). Thus, brain tumor drug discovery is characterized by major obstacles and historical failure.

In a study of CNS drugs entered into clinical trials from 1990 to 2012, CNS drugs were 45% less likely to pass Phase III trials than non-CNS drugs, with 46% failing to show improved efficacy over placebo ([@B109]). Although bevacizumab received FDA approval, other antiangiogenesis drug candidates have been less effective. The Phase III "REGAL" (Recentin in Glioblastoma Alone and with Lomustine) trial comparing cediranib and cediranib + lomustine versus placebo in patients with recurrent GBM failed to reach the primary endpoint of progression-free survival prolongation ([@B15]). By using a different approach, rindopepimut, a conjugate of the EGFRvIII mutation site with an immunogenic carrier protein keyhole limpet hemocyanin, demonstrated efficacy in Phase I and II trials in combination with temozolomide. Progression-free survival and median overall survival (OS) were 10--15 and 22--26 months, respectively, compared with 6 and 15 months in historical controls ([@B208]). Unfortunately, in the Phase III study, rindopepimut failed to meet OS endpoint criteria; however, this was due to a significant outperformance of the control arm (median OS = 20.0 months) compared with the treatment arm (median OS = 20.1 months) ([@B267]). Trials with rindopepimut will continue, but this failure highlights an important obstacle faced when bringing a novel therapy to the market.

Several obstacles impede the drug discovery process for GBM treatment. Challenges include identifying an effective target at the early research stages amid the complex intratumoral molecular heterogeneity, identifying a therapy that is permeable to the BBB, and developing robust clinical trials to assess the effectiveness of the potential treatment. Furthermore, a recent study highlighted the variation in the epigenetic tumor microenvironment of in vitro and in vivo models, suggesting that research with in vitro cancer cell lines is a "therapeutic roadblock" to GBM drug discovery ([@B139]). This study identified a single gene, jumonji C-domain-containing protein 6 (JMJD6), as a potential target. JMJD6 interacts with bromodomain containing 4 (BRD4), and JMJD6 shRNA knockdown was lethal in both in vitro and in vivo models ([@B139]).

As for the pharmacokinetics of the drug, there are several important limitations to consider for any drug candidate. First, the compound must reach the tumor site without diffusing into other tissue and must reach therapeutic concentrations. For example, a retrospective pharmacokinetic analysis of lapatinib after a failed Phase I/II clinical trial revealed that therapeutic concentrations of the drug were not reached ([@B176]). Additionally, CNS drugs must be able to cross the BBB, which means they must have appropriate lipophilicity and size. Lipophilicity is measured by the octanol-water partition coefficient of a compound (ClogP), and CNS drugs optimally have a ClogP = 2 ([@B79]). The size of a compound is measured by its molecular weight and polar surface area, which are optimal below 450 g/mol and 90 Å^2^, respectively, for CNS drugs ([@B171]). This is a large obstacle for biologics, since EGFR antibodies cannot cross the BBB. Generally, only 0.1%--0.2% of an administered antibody crosses the BBB and reaches the tumor site ([@B166]). (Here, it should be noted that bevacizumab likely does not need to cross the BBB to target the VEGF receptors in the lumen of capillaries of blood vessels in the brain.) Drugs could be administered intratumorally, as with the case of DNX-2401. In a Phase I trial, DNX-2401, an oncolytic adenovirus, demonstrated antitumor activity with no dose-limiting side effects ([@B115]). Intratumoral injections, although effective, may be time-consuming, unfamiliar to oncologists, and pose biosafety concerns. Another consideration is the presence of Pgp efflux pumps that remove foreign material escaping past the BBB. Although the BBB is impaired at the tumor site, allowing for increased permeability, the dense endothelium of vasculature providing nutrients to the tumor is not compromised, and therefore most of the BBB remains intact ([@B14]). These issues should be addressed in the preclinical phase, before bringing drug candidates into clinical trials.

Retrospective analysis of EGFR inhibitors provided insight into their failure in GBM clinical trials. EGFR inhibitors are widely and effectively used in preclinical models of GBM; however, clinical trials with these inhibitors failed to detect any improvement in outcome. These tyrosine kinase inhibitors (TKI), namely erlotinib and gefitinib, likely failed clinical trials due to limited brain exposure from Pgp and ABCG2-mediated efflux ([@B3]; [@B40]). Additionally, gefitinib inhibits signaling of EGFR proteins with mutations in exons 19 and 21 of the TK domain that are often absent in gliomas ([@B130]). This phenomenon suggests more rigorous preclinical research should be conducted before expensive clinical trials are initiated.

A few recent successes in TKIs, osimertinib and GDC-0084, should be noted. The third generation EGFR inhibitor osimertinib (AZD9291) has been studied for its efficacy against non-small cell lung cancer (NSCLC) and is undergoing a large Phase I/II trial to determine the maximum tolerated dose in patients with advanced NSCLC (NCT01802632). Preclinical evaluation of osimertinib demonstrated the compound is more BBB permeable than gefitinib and other TKIs ([@B11]). Another TKI, GDC-0084, was demonstrated to cross the BBB in a first-in-human Phase I dose-escalation study in patients with high-grade glioma ([@B238]). Extensive structure-activity relationship analysis on the dual PI3K/mammalian target of rapamycin complex 1 inhibitor revealed that removal of a methyl group at the two position of the pyridine side chain of the purine-based scaffold increased cellular potency and human metabolic stability and decreased efflux ratios ([@B83]). Since BBB permeability has been a major problem with current EGFR TKIs, osimertinib and GDC-0084 both represent exciting inhibitors that have the potential to become efficacious treatments for brain and potentially other cancers.

Although recent efforts have advanced GBM drug discovery, nonpharmacokinetic problems, including clinical trial organization, remain a large obstacle to drug development. Because GBM is an orphan disease, clinical trial participation is low, which prevents the detection of subtle differences in treatment with statistical significance. Other challenges include determination of appropriate controls, stratification according to prognostic factors, and definition of clinical endpoint ([@B175]). In addition, it is difficult to monitor the molecular signature of a brain tumor because surgeries are expensive and risky. It will be important to establish nonimaging methods of determining drug efficacy because targeted therapies may be cytostatic. In addition, biomarkers to measure treatment response will be useful for GBM clinical trials.

VIII. Advances in Drug Delivery {#s38}
===============================

A. Nanocarriers {#s39}
---------------

The current standard of care for GBM, temozolomide, suffers from problems with poor drug delivery. The compound is not soluble under physiologic conditions, easily inactivated via hydrolysis in the cells, and causes harmful side effects because of off-target DNA damage ([@B48]). Furthermore, several clinical trials have failed, such as those with gefitinib and erlotinib, due to the inability of the compounds to pass the BBB. While modifications to the compounds could improve BBB permeability, such modifications may affect target binding or decrease compound potency. Thus, nanocarrier delivery has emerged as a promising approach, especially for drug transport across the BBB using methods such as nanoparticles or prodrugs ([Fig. 10](#F10){ref-type="fig"}).

![Three drug delivery strategies for crossing the blood-brain barrier. In receptor-mediated endocytosis, a drug is conjugated to a ligand that binds to a receptor on the blood-brain barrier to trigger endocytosis. Small lipophilic compounds can be taken up by passive diffusion. Carrier-mediated transport is driven by two major protein families, the solute carrier superfamily and ATP binding cassette transporters, and these transporters can be hijacked for drug delivery.](pr.117.014944f10){#F10}

### 1. General Properties of Nanoparticles {#s40}

In general, nanoparticles (NPs) can be classified as organic/polymeric (e.g., liposomes, dendrimers, micelles, and ferritin) or inorganic (e.g., gold NPs, quantum dots, iron oxide, and lanthanide ions) ([@B185]). Organic NPs provide more flexibility in terms of chemistry and structure for fabrication, whereas inorganic NPs have interesting physical properties including particular optical or magnetic features ([@B31]; [@B228]; [@B1]).

There are several important factors influencing the BBB permeability of NPs, including composition, size, charge, and shape ([@B185]). NP size is a fundamental characteristic that determines passive targeting and biodistribution within brain tumors. NPs within 5--100 nm had selective penetration into brain tumors, with low accumulation in healthy brain tissue, due to the enhanced permeability and retention effect ([@B30]; [@B48]; [@B141]; [@B103]). Surface charge is also an important factor determining NP transport across the BBB. Neutral and low concentrations of anionic NPs can be used safely as colloidal drug carriers to the brain. In contrast, high concentration anionic NPs (zeta potential between −15 and −60 mV) and cationic NPs (zeta potential between 15 and 45 mV) compromise BBB integrity ([@B121]). In general, most of the NP formulations for brain delivery have a moderate zeta potential (between ±1 and ±15 mV). Therefore, NP surface charge can influence toxicity and distribution profiles. In addition, drug carrier activity can be enhanced by conjugation with different types of ligands. For example, ligands can be: 1) capable of mediating protein adsorption (e.g., polysorbate) ([@B162]), 2) capable of increasing charge and hydrophobicity (e.g., amphiphilic peptides), 3) able to improve blood circulation (e.g., polyethylene glycol) ([@B95]), and 4) able to target macromolecules on the cell membrane directly such as peptides (e.g., RGD, NGR, and pep-1 peptides), proteins (transferrin), and antibodies (e.g., nicotinic acetylcholine receptor, EGFR, IL13R*α*2, and LRP1 antibodies) ([@B239]; [@B195]; [@B187]). Overall, several parameters can influence the ability of NPs to transverse the BBB. Therefore, it is important that appropriate NP systems be designed and modulated to meet the objectives of the proposed function.

### 2. Nanocarriers in Clinical Trials {#s41}

With proper characteristics in terms of composition, size, shape, surface charge, and coating chemistry, many nanocarriers can be transported effectively across the BBB in both in vitro and in vivo models by endocytosis and/or transcytosis. Subsequently, clinical trials using nanocarriers to deliver drugs and target brain tumors have been conducted ([Table 3](#T3){ref-type="table"}).

###### 

Nanoparticle-based agents in preclinical and clinical trials for brain tumors (clinicaltrials.gov)

  Name                     Material               Target ligand                                              Therapeutic agent    Size (nm)   Status
  ------------------------ ---------------------- ---------------------------------------------------------- -------------------- ----------- ----------------------------
  Organic/Polymer                                                                                                                             
  NL CPT-11 ([@B35])       Liposome               ---                                                        irinotecan           96--101     Phase I NCT00734682
  SGT-53 ([@B24])          Liposome               transferrin                                                wild-type P53 gene   90          Phase II NCT02340156
  SGT-94 ([@B198])         Liposome               transferrin                                                RB94 gene            108         Phase I NCT01517464
  2B3-101 ([@B61])         Liposome               glutathione                                                doxorubicin          95          Phase I/IIa NCT01386580
  Inorganic                                                                                                                                   
  Cornell dots ([@B164])   silica nanoparticles   cyclic arginine--glycine--aspartic acid (cRGDY) peptides   ---                  7           Phase 0 NCT01266096
  NU-0129                  gold nanoparticles     spherical nucleic acid for *BCL2L12*                       ---                              Phase 0/1 NCT03020017
  NanoTherm ([@B125])      iron oxide             ---                                                        ---                  15          Approved in Europe in 2013

There are NP-based systems that have progressed to clinical trials ([@B8]). For example, CPT-11 is a nanoliposomal irinotecan without a targeting molecule that was evaluated in Phase I studies in patients with recurrent high-grade gliomas (NCT00734682). In a Phase II clinical trial, SGT-53 was combined with temozolomide to treat patients with recurrent malignant gliomas, with the aim of evaluating tumor cell death, antitumor efficacy, safety, and overall survival (NCT02340156). SGT-53, a nanocarrier developed by SynerGene Therapeutics, Inc., is composed of cationic liposomes encapsulating a plasmid of P53 tumor suppressor and conjugating antitransferrin receptor antibody. Another gene therapy that has reached clinical trials is SGT-94, which contains RB94 plasmid DNA that encodes a truncated form of the RB gene, in a liposome with an antitransferrin receptor antibody ([@B198]). SGT-94 was found to cross the BBB and, therefore, may be a promising delivery method for GBM treatment ([@B110]). Regarding liposome-based nanocarriers, 2B3-101 is composed of PEGylated liposomal doxorubicin displaying glutathione as a targeting ligand for glutathione transporters. 2B3--101 enhanced doxorubicin delivery to the brain extracellular space compared with free doxorubicin and completed a Phase I/IIa clinical trial ([@B61]). In addition to liposomal-based systems, inorganic nanocarriers such as Cornell Dots; silica NPs conjugated with cyclic arginine--glycine--aspartic acid (cRGDY) peptides; and NU-0129, small gold NPs attached to spherical nucleic acids targeted for *BCL2L12*, are being tested ([@B164]). Aminosilane-coated superparamagnetic iron oxide, called NanoTherm, was approved in Europe in 2013 to treat GBM. Treatment of GBM patients with hyperthermia plus radiotherapy with NanoTherm resulted in median overall survival of 13.4 months following first recurrence compared with 6.2 months with conventional treatments in a previous study population ([@B125]). These clinical trials demonstrate the ability of NPs to increase compound concentration near GBM tumors and potentially improve potency and efficacy.

B. Prodrugs {#s42}
-----------

Due to the presence of the BBB, only a small percentage of the administered drug reaches the brain. While NPs are a viable method to overcome this issue, another attractive chemical modification-based strategy, the prodrug, has been designed to increase BBB permeability.

A prodrug is a complex formed between a drug and a chemical moiety that increases its solubility or cell permeability ([@B114]). Release of the active drug is controlled at the specific organ or tissue in the body, depending on the unique cellular conditions of each location, such as pH, enzyme distribution, and transporter expression ([@B74]; [@B254]). Prodrugs are designed to overcome various physicochemical and biopharmaceutical obstacles such as low solubility in water or lipid membranes, low target selectivity, chemical instability, and toxicity ([@B173]).

Multiple prodrug strategies have been employed to facilitate transport into the CNS ([Table 4](#T4){ref-type="table"}). Lipidization of the therapeutic molecule can enhance passive diffusion by masking polar groups on the parent drug. The classic example is the acetylation of the hydroxyl group of morphine to procure heroin. Because heroin is more lipophilic than morphine, brain uptake is 100-fold greater for heroin than for morphine ([@B150]). However, although increasing lipophilicity enhances transport of drugs across the BBB, it also increases uptake in other tissues, potentially causing off-target toxicity. As another prodrug strategy, chemical delivery systems (CDS) link an active drug molecule to a lipophilic carrier that is oxidized to the hydrophilic form in the brain. This process results in a sustained and enhanced brain-specific release of free drug. CDS have improved brain targeting for several molecules, including zidovudine (AZT), ganciclovir, benzylpenicillin, and estradiol. For example, attaching a redox-based CDS to estradiol prolongs half-life in the brain ([@B143]), although recent studies have found high quantities of estradiol still accumulate in the uterus upon treatment ([@B169]). Carrier-drug conjugates have transporters within the brain capillary endothelium and deliver compounds that are fundamental to normal brain function, e.g., large neutral amino acid transporter ([@B68]), glucose transporter ([@B51]), sodium-dependent vitamin C transporter 2 ([@B129]), peptide transporters, monocarboxylic acid transporters, organic cation transporters, organic anion transporters, and concentrative nucleoside and nucleotide transporters ([@B21]). Prodrugs with close structural resemblance to substrates of these transporters will be recognized by them. Therefore, these transporters have become targets for drug/prodrug design and transport across the BBB. Ligand-drug conjugates may undergo receptor-mediated transport through the BBB, e.g., insulin, transferrin, leptin, peptides, and antibodies ([@B57]; [@B59]; [@B106]). The activities depend on the affinity of the ligand for its receptor; high-affinity ligands prevent systemic toxicity, but can become trapped in the CNS ([@B142]). In addition, researchers have synthesized active drugs conjugated to brain-targeting moieties, a linear chain tertiary amine (*N*,*N*-dimethyl amino) and cyclic tertiary amine (scopine), to achieve better brain uptake ([@B118]; [@B233]). Furthermore, antibody-drug conjugates as targeted drug delivery systems are a promising novel strategy. For example, anti-EGFR antibody-drug conjugates, like ABT-414, may be useful as a monotherapy or in combination with temozolomide (for an extensive review, see [@B62]). A novel cell-based drug delivery system takes advantage of postoperative inflammatory signals such as IL-8 and CXCL1/KC to deliver paclitaxel in neutrophils to GBM tumors ([@B251]). This neutrophil-based drug delivery system effectively slows recurrent tumor growth in vivo; however, it does not enhance the suppression of primary glioma growth. Nonetheless, novel drug delivery systems have the potential to improve the efficacy of small molecules.

###### 

Prodrug strategies for the transport of drugs into the CNS

  Strategy                           Example                                         Chemical Structure          Action
  ---------------------------------- ----------------------------------------------- --------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------
  Lipidization                       Heroin (Fernandez et al., 2003)                 ![](pr.117.014944fx1.jpg)   Acetylation of the hydroxyl group changes the physicochemical properties of heroin to favor brain uptake.
  Chemical delivery system           Estradiol-CDS (Estredox) ([@B143])              ![](pr.117.014944fx2.jpg)   After oxidation and hydrolysis, the concentration of estradiol CDS in rat brain was elevated four to five times longer than after estradiol treatment.
  Carrier-drug conjugates            LAT1 ([@B68])                                   ![](pr.117.014944fx3.jpg)   The conversion of dopamine into its *α*-amino acid, [l]{.smallcaps}-dopa, enables the brain to uptake dopamine via LAT1.
                                     GLUT1 (Fernandez et al., 2003)                  ![](pr.117.014944fx4.jpg)   Dopamine linked to the C6 position of glucose had the best affinity for GLUT1.
                                     SVCT2 ([@B129])                                 ![](pr.117.014944fx5.jpg)   When nipecotic, kynurenic, and diclophenamic acids were conjugated to ascorbic acid, interaction with SVCT2 transporters improved.
  Ligand-drug conjugates             Insulin/transferrin ([@B57]; [@B59]; [@B233])   ---                         CNS accumulation of methotrexate is improved by conjugating it to an antibody (OX-26), which is recognized by the transferrin receptor.
  Targeting moiety-drug conjugates   *N*,*N*-dimethyl amino ([@B118])                ![](pr.117.014944fx6.jpg)   Conjugation with *N*,*N*-dimethyl amino significantly enhanced the brain-uptake efficiency of dexibuprofen, naproxen, 5-fluorouracil, and dopamine.
                                     Scopine, cyclic tertiary amine ([@B233])        ![](pr.117.014944fx7.jpg)   Chlorambucil-scopine prodrug significantly improved the cellular uptake both in vitro and in vivo.

GLUT1, glucose transporter; LAT, large neutral amino acid transporter; SVCT2, sodium-dependent vitamin C transporter 2.

IX. Conclusions and Future Directions {#s43}
=====================================

Treatment of GBM is a complex and formidable, but not unsolvable, problem. The girth of available genomic information directs research strategies, allowing researchers to pursue meaningful hypotheses supported by patterns in population-level genomics. In tandem, novel proteomic tools are a valuable resource that will enhance our understanding of GBM tumor complexity. Genomic methods have already revealed a molecular fingerprint of the disease and pathways on which to focus our research efforts. Despite the emergence of more specific molecular classifications of GBM, targeted therapies to treat specific GBM subtypes are not yet realized. Numerous failed clinical trials suggest combination therapies will likely be the most promising method of GBM treatment, and emphasis should be applied to drug design and pharmacokinetic properties. With this study, we have identified 20 genes that may play important roles in GBM progression. These genes should be validated as potential targets for GBM drug discovery, as they correlate with poor overall patient survival. We have also uncovered novel transcription factors and signaling molecules involved in GBM that may regulate EGFR signaling. Targeting transcription factors and membrane proteins upstream of EGFR signaling may prove a promising therapeutic strategy for the treatment of GBM. Several genes identified in our analysis have been linked with GBM or EGFR signaling in previous studies. It should be noted that gene expression of the 20 targets could be a consequence of oncogenic stress, rather than tumor growth, and further target validation is necessary. This analysis may reorganize research priorities toward targeting receptors and proteins involved in glioma progression. In the future, both genomic and proteomic approaches will be standard tools not only to identify novel drug targets, but also to identify noninvasive biomarkers for diagnosis and treatment response.
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